IN165561B - - Google Patents

Info

Publication number
IN165561B
IN165561B IN127/CAL/86A IN127CA1986A IN165561B IN 165561 B IN165561 B IN 165561B IN 127CA1986 A IN127CA1986 A IN 127CA1986A IN 165561 B IN165561 B IN 165561B
Authority
IN
India
Application number
IN127/CAL/86A
Other languages
English (en)
Inventor
Marc Ballivet
Stuart Alan Kauffman
Original Assignee
Marc Ballivet
Stuart Alan Kauffman
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=4209046&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN165561(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Marc Ballivet, Stuart Alan Kauffman filed Critical Marc Ballivet
Priority to IN228/CAL/89A priority Critical patent/IN169027B/en
Publication of IN165561B publication Critical patent/IN165561B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1093—General methods of preparing gene libraries, not provided for in other subgroups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/485—Epidermal growth factor [EGF], i.e. urogastrone
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1048—SELEX
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/64—General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/66—General methods for inserting a gene into a vector to form a recombinant vector using cleavage and ligation; Use of non-functional linkers or adaptors, e.g. linkers containing the sequence for a restriction endonuclease
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C12N15/68—Stabilisation of the vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2468—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1) acting on beta-galactose-glycoside bonds, e.g. carrageenases (3.2.1.83; 3.2.1.157); beta-agarase (3.2.1.81)
    • C12N9/2471—Beta-galactosidase (3.2.1.23), i.e. exo-(1-->4)-beta-D-galactanase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01023—Beta-galactosidase (3.2.1.23), i.e. exo-(1-->4)-beta-D-galactanase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
IN127/CAL/86A 1985-03-30 1986-02-20 IN165561B (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
IN228/CAL/89A IN169027B (de) 1985-03-30 1989-03-21

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH137985 1985-03-30
PCT/CH1985/000099 WO1986005803A1 (fr) 1985-03-30 1985-06-17 Procede d'obtention d'adn, arn, peptides, polypeptides ou proteines, par une technique de recombinaison d'adn

Publications (1)

Publication Number Publication Date
IN165561B true IN165561B (de) 1989-11-18

Family

ID=4209046

Family Applications (2)

Application Number Title Priority Date Filing Date
IN127/CAL/86A IN165561B (de) 1985-03-30 1986-02-20
IN228/CAL/89A IN169027B (de) 1985-03-30 1989-03-21

Family Applications After (1)

Application Number Title Priority Date Filing Date
IN228/CAL/89A IN169027B (de) 1985-03-30 1989-03-21

Country Status (14)

Country Link
US (7) US5723323A (de)
EP (3) EP0590689B2 (de)
JP (4) JP2584613B2 (de)
CN (1) CN86102090A (de)
AU (1) AU4434585A (de)
CA (2) CA1339937C (de)
CH (1) CH0229046H1 (de)
DE (7) DE3590766T (de)
FR (1) FR2579618B1 (de)
GB (1) GB2183661B (de)
HK (1) HK20292A (de)
IN (2) IN165561B (de)
SG (1) SG7992G (de)
WO (1) WO1986005803A1 (de)

Families Citing this family (750)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5866363A (en) * 1985-08-28 1999-02-02 Pieczenik; George Method and means for sorting and identifying biological information
US5824469A (en) * 1986-07-17 1998-10-20 University Of Washington Method for producing novel DNA sequences with biological activity
US20060008806A1 (en) * 1986-07-17 2006-01-12 University Of Washington Method for producing novel DNA sequence with biological activity
US5266684A (en) 1988-05-02 1993-11-30 The Reagents Of The University Of California Peptide mixtures
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
CA2009996A1 (en) * 1989-02-17 1990-08-17 Kathleen S. Cook Process for making genes encoding random polymers of amino acids
US7413537B2 (en) 1989-09-01 2008-08-19 Dyax Corp. Directed evolution of disulfide-bonded micro-proteins
JP3127158B2 (ja) * 1989-10-05 2001-01-22 オプテイン，インコーポレイティド 新規の遺伝子及びポリペチドの無細胞合成並びに単離
US5747334A (en) * 1990-02-15 1998-05-05 The University Of North Carolina At Chapel Hill Random peptide library
US5498538A (en) * 1990-02-15 1996-03-12 The University Of North Carolina At Chapel Hill Totally synthetic affinity reagents
DE69132902D1 (de) * 1990-02-15 2002-02-21 Univ North Carolina Chapel Hill Methoden zur identifizierung heterofunktionaler fusionsproteine
US5639595A (en) * 1990-05-01 1997-06-17 Isis Phamaceuticals, Inc. Identification of novel drugs and reagents
US5427908A (en) * 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US6759392B1 (en) 1990-06-11 2004-07-06 Gilead Sciences, Inc. High affinity RNA ligands of basic fibroblast growth factor
US6083696A (en) * 1990-06-11 2000-07-04 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands exponential enrichment: blended selex
US6569620B1 (en) 1990-06-11 2003-05-27 Somalogic, Inc. Method for the automated generation of nucleic acid ligands
US5270163A (en) * 1990-06-11 1993-12-14 University Research Corporation Methods for identifying nucleic acid ligands
US5712375A (en) * 1990-06-11 1998-01-27 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: tissue selex
US5686592A (en) * 1990-06-11 1997-11-11 Nexstar Pharmaceuticals, Inc. High-affinity oligonucleotide ligands to immunoglobulin E (IgE)
US5496938A (en) 1990-06-11 1996-03-05 Nexstar Pharmaceuticals, Inc. Nucleic acid ligands to HIV-RT and HIV-1 rev
US20040132067A1 (en) * 1990-06-11 2004-07-08 Somalogic, Inc. Systematic evolution of ligands by exponential enrichment: photoselection of nucleic acid ligands and solution selex
US5580737A (en) * 1990-06-11 1996-12-03 Nexstar Pharmaceuticals, Inc. High-affinity nucleic acid ligands that discriminate between theophylline and caffeine
US5837834A (en) * 1990-06-11 1998-11-17 Nexstar Pharmaceuticals, Inc. High affinity HKGF nucleic acid ligands and inhibitors
US5763173A (en) * 1990-06-11 1998-06-09 Nexstar Pharmaceuticals, Inc. Nucleic acid ligand inhibitors to DNA polymerases
US5629155A (en) * 1990-06-11 1997-05-13 Nexstar Pharmaceuticals, Inc. High-affinity oligonucleotide ligands to immunoglobulin E (IgE)
US5756287A (en) * 1990-06-11 1998-05-26 Nexstar Pharmaceuticals, Inc. High affinity HIV integrase inhibitors
US5763177A (en) * 1990-06-11 1998-06-09 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: photoselection of nucleic acid ligands and solution selex
US6127119A (en) * 1990-06-11 2000-10-03 Nexstar Pharmaceuticals, Inc. Nucleic acid ligands of tissue target
US5837456A (en) * 1990-06-11 1998-11-17 Nexstar Pharmaceuticals, Inc. High affinity oligonucleotide ligands to chorionic gonadotropin hormone and related glycoprotein hormones
US5853984A (en) * 1990-06-11 1998-12-29 Nexstar Pharmaceuticals, Inc. Use of nucleic acid ligands in flow cytometry
US6346611B1 (en) 1990-06-11 2002-02-12 Gilead Sciences, Inc. High affinity TGfβ nucleic acid ligands and inhibitors
US5795721A (en) * 1990-06-11 1998-08-18 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands of ICP4
US5693502A (en) * 1990-06-11 1997-12-02 Nexstar Pharmaceuticals, Inc. Nucleic acid ligand inhibitors to DNA polymerases
US5763566A (en) * 1990-06-11 1998-06-09 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: tissue SELEX
US20060084797A1 (en) * 1990-06-11 2006-04-20 Gilead Sciences, Inc. High affinity TGFbeta nucleic acid ligands and inhibitors
US6465188B1 (en) 1990-06-11 2002-10-15 Gilead Sciences, Inc. Nucleic acid ligand complexes
US5527894A (en) * 1990-06-11 1996-06-18 Nexstar Pharmacueticals, Inc. Ligands of HIV-1 tat protein
US5861254A (en) * 1997-01-31 1999-01-19 Nexstar Pharmaceuticals, Inc. Flow cell SELEX
US5654151A (en) * 1990-06-11 1997-08-05 Nexstar Pharmaceuticals, Inc. High affinity HIV Nucleocapsid nucleic acid ligands
US5648214A (en) * 1990-06-11 1997-07-15 University Research Corporation High-affinity oligonucleotide ligands to the tachykinin substance P
US6124449A (en) * 1990-06-11 2000-09-26 Nexstar Pharmaceuticals, Inc. High affinity TGFβ nucleic acid ligands and inhibitors
US5811533A (en) * 1990-06-11 1998-09-22 Nexstar Pharmaceuticals, Inc. High-affinity oligonucleotide ligands to vascular endothelial growth factor (VEGF)
US5688935A (en) * 1990-06-11 1997-11-18 Nexstar Pharmaceuticals, Inc. Nucleic acid ligands of tissue target
US6232071B1 (en) * 1990-06-11 2001-05-15 Gilead Sciences, Inc. Tenascin-C nucleic acid ligands
US5707796A (en) * 1990-06-11 1998-01-13 Nexstar Pharmaceuticals, Inc. Method for selecting nucleic acids on the basis of structure
US5731144A (en) * 1990-06-11 1998-03-24 Nexstar Pharmaceuticals, Inc. High affinity TGFβ nucleic acid ligands
US5789157A (en) * 1990-06-11 1998-08-04 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: tissue selex
US5750342A (en) * 1990-06-11 1998-05-12 Nexstar Pharmaceuticals, Inc. Nucleic acid ligands of tissue target
US5459015A (en) * 1990-06-11 1995-10-17 Nexstar Pharmaceuticals, Inc. High-affinity RNA ligands of basic fibroblast growth factor
US6465189B1 (en) * 1990-06-11 2002-10-15 Gilead Sciences, Inc. Systematic evolution of ligands by exponential enrichment: blended selex
US5789163A (en) * 1990-06-11 1998-08-04 Nexstar Pharmaceuticals, Inc. Enzyme linked oligonucleotide assays (ELONAS)
US6011020A (en) * 1990-06-11 2000-01-04 Nexstar Pharmaceuticals, Inc. Nucleic acid ligand complexes
US5683867A (en) * 1990-06-11 1997-11-04 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: blended SELEX
US5972599A (en) * 1990-06-11 1999-10-26 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands of cytokines
US5962219A (en) 1990-06-11 1999-10-05 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: chemi-selex
US6140490A (en) * 1996-02-01 2000-10-31 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands of complement system proteins
US6261774B1 (en) 1990-06-11 2001-07-17 Gilead Sciences, Inc. Truncation selex method
US5766853A (en) * 1990-06-11 1998-06-16 Nexstar Pharmaceuticals, Inc. Method for identification of high affinity nucleic acid ligands to selectins
US5660985A (en) 1990-06-11 1997-08-26 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands containing modified nucleotides
US5668264A (en) * 1990-06-11 1997-09-16 Nexstar Pharmaceuticals, Inc. High affinity PDGF nucleic acid ligands
US6344321B1 (en) * 1990-06-11 2002-02-05 Gilead Sciences, Inc. Nucleic acid ligands which bind to hepatocyte growth factor/scatter factor (HGF/SF) or its receptor c-met
US5543293A (en) * 1990-06-11 1996-08-06 Nexstar Pharmaceuticals, Inc. DNA ligands of thrombin
US5726017A (en) * 1990-06-11 1998-03-10 Nexstar Pharmaceuticals, Inc. High affinity HIV-1 gag nucleic acid ligands
US5780228A (en) * 1990-06-11 1998-07-14 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands to lectins
US6395888B1 (en) 1996-02-01 2002-05-28 Gilead Sciences, Inc. High affinity nucleic acid ligands of complement system proteins
US5846713A (en) * 1990-06-11 1998-12-08 Nexstar Pharmaceuticals, Inc. High affinity HKGF nucleic acid ligands and inhibitors
US5869641A (en) * 1990-06-11 1999-02-09 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands of CD4
US6610841B1 (en) 1997-12-18 2003-08-26 Gilead Sciences, Inc. Nucleotide-based prodrugs
US5472841A (en) * 1990-06-11 1995-12-05 Nexstar Pharmaceuticals, Inc. Methods for identifying nucleic acid ligands of human neutrophil elastase
US5705337A (en) * 1990-06-11 1998-01-06 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: chemi-SELEX
US5503978A (en) * 1990-06-11 1996-04-02 University Research Corporation Method for identification of high affinity DNA ligands of HIV-1 reverse transcriptase
ATE318832T1 (de) * 1990-06-11 2006-03-15 Gilead Sciences Inc Verfahren zur vervendung von nukleinsäureliganden
US5874557A (en) * 1990-06-11 1999-02-23 Nexstar Pharmaceuticals, Inc. Nucleic acid ligand inhibitors to DNA polymerases
US6716580B2 (en) 1990-06-11 2004-04-06 Somalogic, Inc. Method for the automated generation of nucleic acid ligands
US5849890A (en) * 1990-06-11 1998-12-15 Nexstar Pharmaceuticals, Inc. High affinity oligonucleotide ligands to chorionic gonadotropin hormone and related glycoprotein hormones
US6001988A (en) * 1990-06-11 1999-12-14 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands to lectins
US5637682A (en) * 1990-06-11 1997-06-10 Nexstar Pharmaceuticals, Inc. High-affinity oligonucleotide ligands to the tachykinin substance P
US5637459A (en) * 1990-06-11 1997-06-10 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: chimeric selex
US5674685A (en) * 1990-06-11 1997-10-07 Nexstar Pharmaceuticals, Inc. High affinity PDGF nucleic acid ligands
US5723289A (en) * 1990-06-11 1998-03-03 Nexstar Pharmaceuticals, Inc. Parallel selex
US6177557B1 (en) 1990-06-11 2001-01-23 Nexstar Pharmaceuticals, Inc. High affinity ligands of basic fibroblast growth factor and thrombin
US5731424A (en) * 1990-06-11 1998-03-24 Nexstar Pharmaceuticals, Inc. High affinity TGFβ nucleic acid ligands and inhibitors
US5587468A (en) * 1990-06-11 1996-12-24 University Research Corporation High affinity nucleic acid ligands to HIV integrase
US6030776A (en) * 1990-06-11 2000-02-29 Nexstar Pharmaceuticals, Inc. Parallel SELEX
US5864026A (en) * 1990-06-11 1999-01-26 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: tissue selex
US6280932B1 (en) 1990-06-11 2001-08-28 Gilead Sciences, Inc. High affinity nucleic acid ligands to lectins
US6001577A (en) * 1998-06-08 1999-12-14 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: photoselection of nucleic acid ligands and solution selex
US5641629A (en) * 1990-06-11 1997-06-24 Nexstar Pharmacueticals Inc Spectroscopically detectable nucleic acid ligands
US5635615A (en) * 1990-06-11 1997-06-03 Nexstar Pharmaceuticals, Inc. High affinity HIV nucleocapsid nucleic acid ligands
US6696252B2 (en) 1990-06-11 2004-02-24 Gilead Sciences, Inc. High-affinity oligonucleotide ligands to vascular endothelial growth factor (VEGF)
US5874218A (en) * 1990-06-11 1999-02-23 Nexstar Pharmaceuticals, Inc. Method for detecting a target compound in a substance using a nucleic acid ligand
US5567588A (en) * 1990-06-11 1996-10-22 University Research Corporation Systematic evolution of ligands by exponential enrichment: Solution SELEX
US6331394B1 (en) 1991-06-10 2001-12-18 Gilead Sciences, Inc. Nucleic acid ligands to integrins
US5723286A (en) 1990-06-20 1998-03-03 Affymax Technologies N.V. Peptide library and screening systems
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US7063943B1 (en) 1990-07-10 2006-06-20 Cambridge Antibody Technology Methods for producing members of specific binding pairs
US6916605B1 (en) * 1990-07-10 2005-07-12 Medical Research Council Methods for producing members of specific binding pairs
US5843701A (en) * 1990-08-02 1998-12-01 Nexstar Pharmaceticals, Inc. Systematic polypeptide evolution by reverse translation
DK1279731T3 (da) 1991-03-01 2007-09-24 Dyax Corp Fremgangsmåde til udvikling af bindende miniproteiner
US6762290B1 (en) 1999-07-29 2004-07-13 Gilead Sciences, Inc. High affinity vascular endothelial growth factor (VEGF) receptor nucleic acid ligands and inhibitors
AU732820B2 (en) 1995-06-02 2001-05-03 Nexstar Pharmaceuticals, Inc. High-affinity oligonucleotide ligands to growth factors
US6028186A (en) * 1991-06-10 2000-02-22 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands of cytokines
AU2313392A (en) * 1991-08-01 1993-03-02 University Research Corporation Systematic polypeptide evolution by reverse translation
US5733731A (en) * 1991-10-16 1998-03-31 Affymax Technologies N.V. Peptide library and screening method
US5270170A (en) * 1991-10-16 1993-12-14 Affymax Technologies N.V. Peptide library and screening method
ES2227512T3 (es) * 1991-12-02 2005-04-01 Medical Research Council Produccion de anticuerpos contra auto-antigenos a partir de repertorios de segmentos de anticuerpos fijados en un fago.
US5656467A (en) * 1992-01-09 1997-08-12 The Trustees Of The University Of Pennsylvania Methods and materials for producing gene libraries
CA2132306C (en) * 1992-03-16 2012-07-10 Jacob N. Wohlstadter Selection methods
US5869644A (en) * 1992-04-15 1999-02-09 The Johns Hopkins University Synthesis of diverse and useful collections of oligonucleotidies
US5719273A (en) * 1993-06-14 1998-02-17 Nexstar Pharmaceuticals, Inc. Palladium catalyzed nucleoside modifications methods using nucleophiles and carbon monoxide
US5998142A (en) * 1993-09-08 1999-12-07 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: chemi-SELEX
US6458539B1 (en) 1993-09-17 2002-10-01 Somalogic, Inc. Photoselection of nucleic acid ligands
CA2173990A1 (en) * 1993-10-12 1995-04-20 Narasinga Rao A library of glyco-peptides useful for identification of cell adhesion inhibitors
US20060078561A1 (en) * 1994-01-31 2006-04-13 The Trustees Of Boston University Polyclonal antibody libraries
PT744958E (pt) 1994-01-31 2003-11-28 Univ Boston Bancos de anticorpos policlonais
US6395547B1 (en) 1994-02-17 2002-05-28 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US6335160B1 (en) * 1995-02-17 2002-01-01 Maxygen, Inc. Methods and compositions for polypeptide engineering
US6165793A (en) * 1996-03-25 2000-12-26 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US5605793A (en) * 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
US6406855B1 (en) 1994-02-17 2002-06-18 Maxygen, Inc. Methods and compositions for polypeptide engineering
US6995017B1 (en) 1994-02-17 2006-02-07 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US6309883B1 (en) * 1994-02-17 2001-10-30 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US20060257890A1 (en) 1996-05-20 2006-11-16 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US5837458A (en) 1994-02-17 1998-11-17 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US6117679A (en) 1994-02-17 2000-09-12 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US7153948B2 (en) 1994-04-25 2006-12-26 Gilead Sciences, Inc. High-affinity oligonucleotide ligands to vascular endothelial growth factor (VEGF)
US6682886B1 (en) 1994-04-28 2004-01-27 Gilead Sciences, Inc. Bivalent binding molecules of 7 transmembrane G protein-coupled receptors
US6010861A (en) * 1994-08-03 2000-01-04 Dgi Biotechnologies, Llc Target specific screens and their use for discovering small organic molecular pharmacophores
US6048698A (en) * 1994-09-20 2000-04-11 Nexstar Pharmaceuticals, Inc. Parallel SELEX™
CA2200684A1 (en) * 1994-09-21 1996-03-28 Cytogen Corporation Antigen binding peptides (abtides) from peptide libraries
US5885577A (en) * 1994-09-21 1999-03-23 Cytogen Corporation Antigen binding peptides (abtides) from peptide libraries
AU732961B2 (en) * 1995-05-03 2001-05-03 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: tissue selex
US6013443A (en) * 1995-05-03 2000-01-11 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: tissue SELEX
US5859228A (en) * 1995-05-04 1999-01-12 Nexstar Pharmaceuticals, Inc. Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes
US8071737B2 (en) 1995-05-04 2011-12-06 Glead Sciences, Inc. Nucleic acid ligand complexes
US5723594A (en) * 1995-06-07 1998-03-03 Nexstar Pharmaceuticals, Inc. High affinity PDGF nucleic acid ligands
US20010053523A1 (en) * 1995-06-02 2001-12-20 M&E Biotech A/S. Method for identification of biologically active peptides and nucleic acids
EP2080813B1 (de) * 1995-06-07 2011-01-05 Gilead Sciences, Inc. Nukleinsäureliganden, die an DNA-Polymerasen binden und diese inhibieren
US5797870A (en) * 1995-06-07 1998-08-25 Indiana University Foundation Pericardial delivery of therapeutic and diagnostic agents
US6475806B1 (en) 1995-06-07 2002-11-05 Praecis Pharmaceuticals, Inc. Anchor libraries and identification of peptide binding sequences
US6699843B2 (en) 1995-06-07 2004-03-02 Gilead Sciences, Inc. Method for treatment of tumors using nucleic acid ligands to PDGF
US6229002B1 (en) 1995-06-07 2001-05-08 Nexstar Pharmaceuticlas, Inc. Platelet derived growth factor (PDGF) nucleic acid ligand complexes
US20090118481A1 (en) * 1995-06-07 2009-05-07 Gilead Sciences, Inc. High Affinity Nucleic Acid Ligands To Lectins
US6183967B1 (en) 1995-06-07 2001-02-06 Nexstar Pharmaceuticals Nucleic acid ligand inhibitors to DNA polymerases
US5830696A (en) 1996-12-05 1998-11-03 Diversa Corporation Directed evolution of thermophilic enzymes
US6939689B2 (en) 1995-12-07 2005-09-06 Diversa Corporation Exonuclease-mediated nucleic acid reassembly in directed evolution
US6352842B1 (en) 1995-12-07 2002-03-05 Diversa Corporation Exonucease-mediated gene assembly in directed evolution
US5965408A (en) 1996-07-09 1999-10-12 Diversa Corporation Method of DNA reassembly by interrupting synthesis
US6358709B1 (en) 1995-12-07 2002-03-19 Diversa Corporation End selection in directed evolution
US6537776B1 (en) * 1999-06-14 2003-03-25 Diversa Corporation Synthetic ligation reassembly in directed evolution
US6713279B1 (en) 1995-12-07 2004-03-30 Diversa Corporation Non-stochastic generation of genetic vaccines and enzymes
US20030219752A1 (en) * 1995-12-07 2003-11-27 Diversa Corporation Novel antigen binding molecules for therapeutic, diagnostic, prophylactic, enzymatic, industrial, and agricultural applications, and methods for generating and screening thereof
US20020028443A1 (en) * 1999-09-27 2002-03-07 Jay M. Short Method of dna shuffling with polynucleotides produced by blocking or interrupting a synthesis or amplification process
US20020164580A1 (en) * 1995-12-07 2002-11-07 Diversa Corporation Combinatorial screening of mixed populations of organisms
US6740506B2 (en) 1995-12-07 2004-05-25 Diversa Corporation End selection in directed evolution
US6361974B1 (en) 1995-12-07 2002-03-26 Diversa Corporation Exonuclease-mediated nucleic acid reassembly in directed evolution
US7018793B1 (en) 1995-12-07 2006-03-28 Diversa Corporation Combinatorial screening of mixed populations of organisms
JP2000504220A (ja) 1996-01-23 2000-04-11 ライガル ファーマシューティカルズ インコーポレイテッド トランス支配性細胞内作用因子ペプチドおよびｒｎａ分子のスクリーニング方法
US6365344B1 (en) * 1996-01-23 2002-04-02 The Board Of Trustees Of The Leland Stanford Junior University Methods for screening for transdominant effector peptides and RNA molecules
US6096548A (en) 1996-03-25 2000-08-01 Maxygen, Inc. Method for directing evolution of a virus
US6506602B1 (en) 1996-03-25 2003-01-14 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US6300065B1 (en) 1996-05-31 2001-10-09 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
US6696251B1 (en) 1996-05-31 2004-02-24 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
US6699658B1 (en) 1996-05-31 2004-03-02 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
US6838238B1 (en) 1996-10-17 2005-01-04 Invitrogen Corporation Morphatides: novel shape and structure libraries
US6426335B1 (en) * 1997-10-17 2002-07-30 Gilead Sciences, Inc. Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes
US6355426B2 (en) 1996-10-31 2002-03-12 Smithkline Beecham Corporation Methods for the characterization and selection of RNA target motifs that bind compounds of pharmaceutical use
US20070009930A1 (en) * 1996-12-18 2007-01-11 Maxygen, Inc. Methods and compositions for polypeptide engineering
AU743305C (en) 1997-01-17 2006-03-30 Maxygen, Inc. Evolution of whole cells and organisms by recursive sequence recombination
US7148054B2 (en) 1997-01-17 2006-12-12 Maxygen, Inc. Evolution of whole cells and organisms by recursive sequence recombination
US6326204B1 (en) 1997-01-17 2001-12-04 Maxygen, Inc. Evolution of whole cells and organisms by recursive sequence recombination
WO1998031700A1 (en) 1997-01-21 1998-07-23 The General Hospital Corporation Selection of proteins using rna-protein fusions
US8207093B2 (en) * 1997-01-21 2012-06-26 The General Hospital Corporation Selection of proteins using RNA-protein fusions
US6261804B1 (en) 1997-01-21 2001-07-17 The General Hospital Corporation Selection of proteins using RNA-protein fusions
US5871924A (en) * 1997-01-27 1999-02-16 Nexstar Pharmaceuticals, Inc. Method for the production of ligands capable of facilitating aminoacyl-RNA synthesis
US6153410A (en) * 1997-03-25 2000-11-28 California Institute Of Technology Recombination of polynucleotide sequences using random or defined primers
US6180341B1 (en) 1997-05-01 2001-01-30 Board Of Regents, The Universiry Of Texas System In vitro scanning saturation mutagenesis of proteins
US7087420B1 (en) 1997-07-17 2006-08-08 Cambia Microbial β-glucuronidase genes, gene products and uses thereof
US6391547B1 (en) * 1997-09-09 2002-05-21 Center For The Application Of Molecular Biology To International Agriculture Microbial β-glucuronidase genes, gene products and uses thereof
US6241701B1 (en) 1997-08-01 2001-06-05 Genetronics, Inc. Apparatus for electroporation mediated delivery of drugs and genes
US6670127B2 (en) 1997-09-16 2003-12-30 Egea Biosciences, Inc. Method for assembly of a polynucleotide encoding a target polypeptide
US6596539B1 (en) 1997-10-31 2003-07-22 Maxygen, Inc. Modification of virus tropism and host range by viral genome shuffling
IL136574A0 (en) * 1997-12-08 2001-06-14 California Inst Of Techn A method for forming a polynucleotide of desired properties
US20030219803A1 (en) * 1997-12-15 2003-11-27 Somalogic, Incorporated Homogeneous detection of a target through nucleic acid ligand-ligand beacon interaction
US20070166741A1 (en) 1998-12-14 2007-07-19 Somalogic, Incorporated Multiplexed analyses of test samples
US6261783B1 (en) 1997-12-15 2001-07-17 Gilead Sciences, Inc. Homogeneous detection of a target through nucleic acid ligand-ligand beacon interaction
US5989823A (en) * 1998-09-18 1999-11-23 Nexstar Pharmaceuticals, Inc. Homogeneous detection of a target through nucleic acid ligand-ligand beacon interaction
US6759243B2 (en) 1998-01-20 2004-07-06 Board Of Trustees Of The University Of Illinois High affinity TCR proteins and methods
US6541011B2 (en) 1998-02-11 2003-04-01 Maxygen, Inc. Antigen library immunization
US7390619B1 (en) 1998-02-11 2008-06-24 Maxygen, Inc. Optimization of immunomodulatory properties of genetic vaccines
FR2782325B1 (fr) 1998-08-12 2002-05-24 Proteus Procede d'identification de sequences polynucleotidiques et/ou des proteines correspondantes a partir d'un echantillon d'acides nucleiques
US7157083B2 (en) * 1998-04-17 2007-01-02 Surrogate Pharmaceutical Pathways, Llc Compositions and methods for treating retroviral infections
US6500617B1 (en) 1998-05-01 2002-12-31 Maxygen, Inc. Optimization of pest resistance genes using DNA shuffling
US7153655B2 (en) * 1998-06-16 2006-12-26 Alligator Bioscience Ab Method for in vitro molecular evolution of protein function involving the use of exonuclease enzyme and two populations of parent polynucleotide sequence
US6365408B1 (en) 1998-06-19 2002-04-02 Maxygen, Inc. Methods of evolving a polynucleotides by mutagenesis and recombination
AU5122499A (en) 1998-07-27 2000-02-21 Genentech Inc. Improved transformation efficiency in phage display through modification of a coat protein
EP1105360B1 (de) 1998-08-17 2009-07-29 Bristol-Myers Squibb Company Identifizierung von verbindung-protein wechselwirkungen mit bibliotheken von gekoppelten protein-nukleinsäure-molekülen
US6773911B1 (en) 1998-11-23 2004-08-10 Amgen Canada Inc. Apoptosis-inducing factor
US6570003B1 (en) * 2001-01-09 2003-05-27 Lexion Genetics Incorporated Human 7TM proteins and polynucleotides encoding the same
WO2000040715A2 (en) * 1999-01-05 2000-07-13 Trustees Of Boston University Improved nucleic acid cloning
EP1151409A1 (de) * 1999-01-18 2001-11-07 Maxygen, Inc. Verfahren zum bevölkern von datenstrukturen für evolutionäre-simulationen
US20030054390A1 (en) * 1999-01-19 2003-03-20 Maxygen, Inc. Oligonucleotide mediated nucleic acid recombination
US20030054360A1 (en) * 1999-01-19 2003-03-20 Larry Gold Method and apparatus for the automated generation of nucleic acid ligands
US20070065838A1 (en) * 1999-01-19 2007-03-22 Maxygen, Inc. Oligonucleotide mediated nucleic acid recombination
US20090130718A1 (en) * 1999-02-04 2009-05-21 Diversa Corporation Gene site saturation mutagenesis
US6329145B1 (en) 1999-02-09 2001-12-11 Gilead Science, Inc. Determining non-nucleic acid molecule binding to target by competition with nucleic acid ligand
AU3719500A (en) 1999-03-05 2000-09-21 Maxygen, Inc. Recombination of insertion modified nucleic acids
US6703240B1 (en) 1999-04-13 2004-03-09 Maxygar, Inc. Modified starch metabolism enzymes and encoding genes for improvement and optimization of plant phenotypes
US7332308B1 (en) 1999-05-21 2008-02-19 The Penn State Research Foundation Incrementally truncated nucleic acids and methods of making same
US6280943B1 (en) 1999-06-17 2001-08-28 Gilead Sciences, Inc. 2′-fluoropyrimidine anti-calf intestinal phosphatase nucleic acid ligands
IL147336A0 (en) 1999-07-07 2002-08-14 Zymogenetics Inc Human cytokine receptor
US6387620B1 (en) * 1999-07-28 2002-05-14 Gilead Sciences, Inc. Transcription-free selex
US6171795B1 (en) 1999-07-29 2001-01-09 Nexstar Pharmaceuticals, Inc. Nucleic acid ligands to CD40ligand
US7005260B1 (en) 2000-01-28 2006-02-28 Gilead Sciences, Inc. Tenascin-C nucleic acid ligands
US6506887B1 (en) 1999-07-29 2003-01-14 Somalogic, Incorporated Conditional-selex
ATE428719T1 (de) * 1999-07-29 2009-05-15 Gilead Sciences Inc Nukleinsäureliganden für den hepatozytischen wachstumsfaktor/dispersionsfaktor (hgf/sf) und seines c-met rezeptors
US6797510B1 (en) * 2001-05-24 2004-09-28 Lexicon Genetics Incorporated Human kinases and polynucleotides encoding the same
US6593125B2 (en) 2000-11-20 2003-07-15 Lexicon Genetics Incorporated Human kinases and polynucleotides encoding the same
US6900045B2 (en) * 2000-08-31 2005-05-31 Lexicon Genetics Incorporated Human kinase proteins and polynucleotides encoding the same
US20080050809A1 (en) * 1999-09-28 2008-02-28 Alejandro Abuin Novel human kinases and polynucleotides encoding the same
US6734010B2 (en) * 2001-05-09 2004-05-11 Lexicon Genetics Incorporated Human kinases and polynucleotides encoding the same
US6586230B1 (en) 2000-10-27 2003-07-01 Lexicon Genetics Incorporated Human kinase and polynucleotides encoding the same
US6841377B1 (en) * 2001-06-13 2005-01-11 Lexicon Genetics Incorporated Human kinase and polynucleotides encoding the same
US6579710B2 (en) * 2000-12-12 2003-06-17 Lexicon Genetics Incorporated Human kinases and polynucleotides encoding the same
US6541252B1 (en) 2000-05-19 2003-04-01 Lexicon Genetics Incorporated Human kinases and polynucleotides encoding the same
US6849425B1 (en) 1999-10-14 2005-02-01 Ixsys, Inc. Methods of optimizing antibody variable region binding affinity
EP1240319A1 (de) * 1999-12-15 2002-09-18 Genentech, Inc. "shotgun scanning", eine methode zur kartierung von funktionellen protein epitopen
US7022479B2 (en) * 2000-01-24 2006-04-04 Compound Therapeutics, Inc. Sensitive, multiplexed diagnostic assays for protein analysis
CA2396810A1 (en) 2000-01-24 2001-07-26 Phylos, Inc. Sensitive, multiplexed diagnostic assays for protein analysis
US20020077464A1 (en) * 2000-01-26 2002-06-20 Turner C. Alexander Novel human neurexin-like proteins and polynucleotides encoding the same
US20050239061A1 (en) * 2000-03-01 2005-10-27 Marshall William S Identification and use of effectors and allosteric molecules for the alteration of gene expression
US7514239B2 (en) 2000-03-28 2009-04-07 Amgen Inc. Nucleic acid molecules encoding beta-like glycoprotein hormone polypeptides and heterodimers thereof
AU2001289284A1 (en) * 2000-04-04 2001-10-15 Enanta Pharmaceuticals, Inc. Methods for identifying peptide aptamers capable of altering a cell phenotype
DK2199393T3 (da) * 2000-04-17 2012-11-26 Dyax Corp Hidtil ukendte fremgangsmåder til opbygning af biblioteker over genetiske pakker, der kollektivt viser medlemmerne af en forskelligartet familie af peptider, polypeptider eller proteiner
US8288322B2 (en) 2000-04-17 2012-10-16 Dyax Corp. Methods of constructing libraries comprising displayed and/or expressed members of a diverse family of peptides, polypeptides or proteins and the novel libraries
WO2001079562A1 (en) * 2000-04-18 2001-10-25 Gilead Sciences, Inc. Aptamer based two-site binding assay
US6479262B1 (en) 2000-05-16 2002-11-12 Hercules, Incorporated Solid phase enzymatic assembly of polynucleotides
WO2001090179A2 (en) * 2000-05-23 2001-11-29 Lexicon Genetics Incorporated Novel human thrombospondin-like proteins and polynucleotides encoding the same
AU2001275337A1 (en) * 2000-06-07 2001-12-17 Lexicon Genetics Incorporated Novel human transporter proteins and polynucleotides encoding the same
WO2001094417A2 (en) * 2000-06-09 2001-12-13 Lexicon Genetics Incorporated Novel human seven transmembrane proteins and polynucleotides encoding the same
US6465632B1 (en) 2000-06-09 2002-10-15 Lexicon Genetics Incorporated Human phosphatases and polynucleotides encoding the same
MXPA02012747A (es) 2000-06-28 2003-09-25 Amgen Inc Moleculas del receptor de linfopoietina estromica timica y sus usos.
US6994963B1 (en) 2000-07-10 2006-02-07 Ambion, Inc. Methods for recombinatorial nucleic acid synthesis
JP2004504330A (ja) * 2000-07-13 2004-02-12 インヴィトロジェン　コーポレーション 溶解マトリクスを用いてタンパク質およびペプチドの迅速な抽出および単離のための方法および組成物
WO2002008408A2 (en) * 2000-07-21 2002-01-31 Trustees Of Boston University Modular vector systems
US7087415B2 (en) * 2000-07-31 2006-08-08 Athena Biotechnologies, Inc. Methods and compositions for directed gene assembly
WO2002011748A1 (en) * 2000-08-07 2002-02-14 Sloan-Kettering Institute For Cancer Research Method and composition for immunization using mixed pools of mutated nucleic acids or peptides
UA81743C2 (uk) 2000-08-07 2008-02-11 Центокор, Инк. МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
US7288390B2 (en) 2000-08-07 2007-10-30 Centocor, Inc. Anti-dual integrin antibodies, compositions, methods and uses
US6902734B2 (en) 2000-08-07 2005-06-07 Centocor, Inc. Anti-IL-12 antibodies and compositions thereof
AU2001286792A1 (en) * 2000-08-22 2002-03-04 Lexicon Genetics Incorporated Novel human 7TM proteins and polynucleotides encoding the same
US6376190B1 (en) 2000-09-22 2002-04-23 Somalogic, Inc. Modified SELEX processes without purified protein
EP2322648A1 (de) * 2000-09-26 2011-05-18 Duke University RNA-Aptamere und Verfahren zu ihrer Identifizierung
WO2002031745A1 (en) * 2000-10-10 2002-04-18 Genencor International, Inc. Information rich libraries
WO2002033116A2 (en) 2000-10-16 2002-04-25 Gilead Sciences, Inc. Nucleic acid ligands to the prostate specific membrane antigen
JP2004533221A (ja) * 2000-10-27 2004-11-04 レキシコン・ジェネティクス・インコーポレーテッド 新規ヒト７ｔｍタンパクおよびそれをコードするポリヌクレオチド
EP1330524A2 (de) * 2000-10-30 2003-07-30 Lexicon Genetics Incorporated Humane 7tm-proteine und dafür kodierende polynukleotiden
AU2002220275A1 (en) * 2000-12-08 2002-06-18 The Board Of Trustees Of The University Of Illinois Mutated class ii major histocompatibility proteins
JP2004517622A (ja) * 2000-12-11 2004-06-17 レキシコン・ジェネティクス・インコーポレーテッド 新規ヒトキナーゼ及び該キナーゼをコードするポリヌクレオチド
US6958213B2 (en) 2000-12-12 2005-10-25 Alligator Bioscience Ab Method for in vitro molecular evolution of protein function
AU2002249854B2 (en) 2000-12-18 2007-09-20 Dyax Corp. Focused libraries of genetic packages
US6852844B1 (en) 2000-12-20 2005-02-08 Lexicon Genetics Incorporated Human protocadherin proteins and polynucleotides encoding the same
US20020086292A1 (en) 2000-12-22 2002-07-04 Shigeaki Harayama Synthesis of hybrid polynucleotide molecules using single-stranded polynucleotide molecules
JP4986370B2 (ja) 2000-12-22 2012-07-25 マックス−プランク−ゲゼルシャフト・ツア・フェルデルング・デア・ヴィッセンシャフテン・エー・ファオ Ｒｇｍおよびそのモジュレーターの用途
WO2002059325A2 (en) * 2000-12-27 2002-08-01 Lexicon Genetics Incorporated Human kinases and polynucleotides encoding the same
JP4061043B2 (ja) 2000-12-28 2008-03-12 株式会社ポストゲノム研究所 ｉｎｖｉｔｒｏ転写／翻訳系によるペプチド等の製造方法
WO2002059287A2 (en) * 2001-01-23 2002-08-01 Lexicon Genetics Incorporated Novel human kinases and polynucleotides encoding the same
JP4689940B2 (ja) * 2001-02-02 2011-06-01 ノビシ バイオテック，リミティド ライアビリティ カンパニー ヘテロ二本鎖の相補性を増大させる方法
US7582423B2 (en) * 2001-02-02 2009-09-01 Novici Biotech Llc Population of polynucleotide sequence variants
US20040142433A1 (en) * 2001-02-02 2004-07-22 Padgett Hal S. Polynucleotide sequence variants
US7838219B2 (en) * 2001-02-02 2010-11-23 Novici Biotech Llc Method of increasing complementarity in a heteroduplex
WO2002065125A1 (en) * 2001-02-13 2002-08-22 Invitrogen Corporation Methods and compositions for isolation of biological macromolecules
EP1373496A4 (de) * 2001-02-22 2004-10-27 Praecis Pharm Inc Verfahren zur identifizierung von einen biologischen vorgang modulierenden peptiden
JP2004532624A (ja) 2001-03-02 2004-10-28 ザイモジェネティクス，インコーポレイティド マウスサイトカイン受容体
AU2002257076A1 (en) 2001-03-19 2002-10-03 President And Fellows Of Harvard College Nucleic acid shuffling
US7807408B2 (en) * 2001-03-19 2010-10-05 President & Fellows Of Harvard College Directed evolution of proteins
WO2002074932A2 (en) 2001-03-20 2002-09-26 Lexicon Genetics Incorporated Novel human kinase and polynucleotides encoding the same
JP2004524043A (ja) 2001-04-06 2004-08-12 レキシコン・ジェネティクス・インコーポレーテッド 新規ヒトキナーゼ及び該キナーゼをコードするポリヌクレオチド
JP2004528841A (ja) * 2001-04-06 2004-09-24 レキシコン・ジェネティクス・インコーポレーテッド 新規ヒトキナーゼおよびそれをコードするポリヌクレオチド
US6644173B2 (en) * 2001-04-11 2003-11-11 Keuring, Incorporated Beverage filter cartridge holder
WO2002090496A2 (en) * 2001-05-03 2002-11-14 Rensselaer Polytechnic Institute Novel methods of directed evolution
WO2002097095A1 (en) * 2001-05-25 2002-12-05 Lexicon Genetics Incorporated Novel human transporter proteins and polynucleotides encoding the same
PT2070939E (pt) 2001-05-25 2014-06-09 Univ Duke Moduladores de agentes farmacológicos
CA2448347C (en) 2001-05-29 2010-09-21 Lexicon Genetics Incorporated Novel human hydroxylases and polynucleotides encoding the same
US20030113714A1 (en) * 2001-09-28 2003-06-19 Belcher Angela M. Biological control of nanoparticles
US20050164515A9 (en) * 2001-06-05 2005-07-28 Belcher Angela M. Biological control of nanoparticle nucleation, shape and crystal phase
US20070160576A1 (en) 2001-06-05 2007-07-12 Genentech, Inc. IL-17A/F heterologous polypeptides and therapeutic uses thereof
US20030148380A1 (en) * 2001-06-05 2003-08-07 Belcher Angela M. Molecular recognition of materials
CA2633171C (en) 2001-06-20 2012-11-20 Genentech, Inc. Antibodies against tumor-associated antigenic target (tat) polypeptides
DE10131441A1 (de) * 2001-06-29 2003-01-30 Henkel Kgaa Eine neue Gruppe von alpha-Amylasen sowie ein Verfahren zur Identifizierung und Gewinnung neuer alpha-Amylasen
US20040204669A1 (en) * 2001-07-05 2004-10-14 Hofmann Gunter A. Apparatus for electroporation mediated delivery for drugs and genes
EP1493028A4 (de) * 2001-07-06 2006-06-14 Genentech Inc Im phagen-display präsentierte liganden der pdz-domäne
US6943001B2 (en) * 2001-08-03 2005-09-13 Diversa Corporation Epoxide hydrolases, nucleic acids encoding them and methods for making and using them
JP2005508619A (ja) * 2001-08-03 2005-04-07 ディヴァーサ コーポレイション エポキシドヒドロラーゼ、それらをコードした核酸及びそれらの作製法と利用法
DE10138753B4 (de) * 2001-08-07 2017-07-20 Henkel Ag & Co. Kgaa Wasch- und Reinigungsmittel mit Hybrid-Alpha-Amylasen
US7647184B2 (en) * 2001-08-27 2010-01-12 Hanall Pharmaceuticals, Co. Ltd High throughput directed evolution by rational mutagenesis
CA2460120A1 (en) 2001-09-18 2003-03-27 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
AU2002330162B2 (en) 2001-10-01 2008-08-07 Takeda Pharmaceutical Company Limited Multi-chain eukaryotic display vectors and uses thereof
US20030073104A1 (en) * 2001-10-02 2003-04-17 Belcher Angela M. Nanoscaling ordering of hybrid materials using genetically engineered mesoscale virus
EP1840211A1 (de) 2001-10-31 2007-10-03 Danisco A/S Pyranoson Dehydratase aus phanerochaete Chrysosporium
ES2624547T3 (es) 2001-11-14 2017-07-14 Janssen Biotech, Inc. Anticuerpos anti il 6, composiciones, métodos y usos
ES2327398T3 (es) * 2001-11-20 2009-10-29 Duke University Biomateriales interfaciales.
AU2002366523A1 (en) * 2001-12-05 2003-06-23 E-Tenna Corporation Capacitively-loaded bent-wire monopole on an artificial magnetic conductor
US7179907B2 (en) 2001-12-18 2007-02-20 Bruce Eaton Antibiotic compounds
WO2003057921A1 (en) * 2001-12-26 2003-07-17 Sloan Kettering Institute For Cancer Research Dna immunization with libraries of minigenes encoding degenerate variants of major histocompatibility class i restricted epitopes
KR20080106369A (ko) 2002-01-02 2008-12-04 제넨테크, 인크. 종양의 진단 및 치료 방법 및 이를 위한 조성물
WO2003064612A2 (en) * 2002-01-28 2003-08-07 Sloan-Kettering Institute For Cancer Research Identification of mutant antigens with enhanced immunogenicity
US7078211B2 (en) * 2002-02-01 2006-07-18 Large Scale Biology Corporation Nucleic acid molecules encoding endonucleases and methods of use thereof
US20030157495A1 (en) * 2002-02-01 2003-08-21 Padgett Hal S. Nucleic acid molecules encoding CEL I endonuclease and methods of use thereof
AU2003217379A1 (en) 2002-02-15 2003-09-09 Somalogic, Inc. Methods and reagents for detecting target binding by nucleic acid ligands
US7662924B2 (en) * 2002-02-22 2010-02-16 The Board Of Trustees Of The University Of Illinois Beta chain-associated regulator of apoptosis
WO2003072738A2 (en) * 2002-02-22 2003-09-04 Board Of Trustees Of The University Of Illinois Beta chain-associated regulator of apoptosis
US20030224404A1 (en) * 2002-02-25 2003-12-04 Manuel Vega High throughput directed evolution of nucleic acids by rational mutagenesis
US20030166010A1 (en) * 2002-02-25 2003-09-04 Affholter Joseph A. Custom ligand design for biomolecular filtration and purification for bioseperation
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
KR20040101502A (ko) 2002-04-16 2004-12-02 제넨테크, 인크. 종양의 진단 및 치료 방법 및 이를 위한 조성물
US7226771B2 (en) 2002-04-19 2007-06-05 Diversa Corporation Phospholipases, nucleic acids encoding them and methods for making and using them
CN102174546A (zh) 2002-04-19 2011-09-07 维莱尼姆公司 磷脂酶，编码磷脂酶的核酸以及制备和应用磷脂酶的方法
US7262012B2 (en) * 2002-05-17 2007-08-28 Alligator Bioscience Ab Method for in vitro molecular evolution of protein function using varied exonuclease digestion in two polynucleotide populations
NZ556507A (en) * 2002-06-03 2010-03-26 Genentech Inc Synthetic antibody phage libraries
EP1558741B1 (de) * 2002-06-14 2008-02-20 Dyax Corporation Rekombination von nukleinsäurebibliotheksmitgliedern
JP2005533794A (ja) * 2002-06-18 2005-11-10 アーケミックス コーポレイション アプタマー−毒素分子およびこれを使用する方法
AU2003261264B2 (en) 2002-07-25 2008-12-11 Archemix Corp. Regulated aptamer therapeutics
EP1576151A4 (de) 2002-08-06 2006-05-17 Verdia Inc Ap1-aminoxidase-varianten
US20040067532A1 (en) * 2002-08-12 2004-04-08 Genetastix Corporation High throughput generation and affinity maturation of humanized antibody
US20050202438A1 (en) * 2002-09-09 2005-09-15 Rene Gantier Rational directed protein evolution using two-dimensional rational mutagenesis scanning
WO2004022593A2 (en) * 2002-09-09 2004-03-18 Nautilus Biotech Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules
US20060020396A1 (en) * 2002-09-09 2006-01-26 Rene Gantier Rational directed protein evolution using two-dimensional rational mutagenesis scanning
US9303262B2 (en) 2002-09-17 2016-04-05 Archemix Llc Methods for identifying aptamer regulators
US20050064508A1 (en) * 2003-09-22 2005-03-24 Semzyme Peptide mediated synthesis of metallic and magnetic materials
EP3502133A1 (de) 2002-09-27 2019-06-26 Xencor, Inc. Optimierte fc-varianten und verfahren zu deren erzeugung
JP3447009B1 (ja) * 2002-10-29 2003-09-16 實 平垣 構築物用構成体およびその製造方法
US20050124565A1 (en) * 2002-11-21 2005-06-09 Diener John L. Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
JP2006516151A (ja) * 2002-11-21 2006-06-22 アーケミックス コーポレイション 改良された薬力学的特性を有する多価アプタマー治療剤ならびにそれらの作製方法および使用法
US8853376B2 (en) 2002-11-21 2014-10-07 Archemix Llc Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
US10100316B2 (en) 2002-11-21 2018-10-16 Archemix Llc Aptamers comprising CPG motifs
US20040197804A1 (en) * 2002-12-03 2004-10-07 Keefe Anthony D. Method for in vitro selection of 2'-substituted nucleic acids
US20050037394A1 (en) * 2002-12-03 2005-02-17 Keefe Anthony D. Method for in vitro selection of 2'-substituted nucleic acids
CA2509568A1 (en) * 2002-12-26 2004-07-15 Applied Research Systems Ars Holding N.V. Spliced variants of lgr6
EP1585767A2 (de) * 2003-01-16 2005-10-19 Genentech, Inc. Phagenbibliothek von synthetischen antikörpern
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
EP3023498B1 (de) 2003-03-06 2018-11-28 BASF Enzymes LLC Amylasen, nukleinsäuren zur codierung davon und verfahren zur herstellung und verwendung davon
EP2853593B1 (de) 2003-03-07 2017-10-04 DSM IP Assets B.V. Hydrolasen, Nucleinsäuren zur Codierung davon sowie Verfahren zur Herstellung und Verwendung davon
EP2341136B1 (de) 2003-04-04 2016-06-08 BASF Enzymes LLC Pektatlyasen, Nukleinsäuren, die für diese kodieren und Verfahren zu deren Herstellung und Verwendung
US20050250106A1 (en) * 2003-04-24 2005-11-10 David Epstein Gene knock-down by intracellular expression of aptamers
US7964714B2 (en) * 2003-05-12 2011-06-21 Potomac Pharmaceuticals Inc. Gene expression suppression agents
US9708410B2 (en) 2003-05-30 2017-07-18 Janssen Biotech, Inc. Anti-tissue factor antibodies and compositions
AU2004254640B2 (en) 2003-07-02 2010-08-26 Bp Corporation North America Inc. Glucanases, nucleic acids encoding them and methods for making and using them
SI2784084T2 (sl) 2003-07-08 2024-02-29 Novartis Pharma Ag Antagonistična protitelesa proti IL-17 A/F heterolognim polipeptidom
KR20060069825A (ko) * 2003-08-01 2006-06-22 제넨테크, 인크. 제한된 다양성을 갖는 항체 ｃｄｒ 폴리펩티드 서열
EP1660631B1 (de) * 2003-08-01 2013-04-24 Life Technologies Corporation Zusammensetzungen und verfahren zur aufreinigung kurzer rna-moleküle
US7741089B2 (en) 2003-08-11 2010-06-22 Verenium Corporation Laccases, nucleic acids encoding them and methods for making and using them
JP2005065575A (ja) * 2003-08-22 2005-03-17 Japan Science & Technology Agency フレームシャッフリングによるタンパク質分子多様性集団の作製
CA2537055A1 (en) * 2003-08-22 2005-04-21 Medimmune, Inc. Humanization of antibodies
US20060134105A1 (en) * 2004-10-21 2006-06-22 Xencor, Inc. IgG immunoglobulin variants with optimized effector function
US8399618B2 (en) 2004-10-21 2013-03-19 Xencor, Inc. Immunoglobulin insertions, deletions, and substitutions
US8883147B2 (en) 2004-10-21 2014-11-11 Xencor, Inc. Immunoglobulins insertions, deletions, and substitutions
SI2161283T1 (sl) 2003-11-17 2014-10-30 Genentech, Inc. Sestavki, ki obsegajo protitelesa proti CD79b, konjugirana na sredstvo, ki inhibira rast, ali na citotoksično sredstvo, in postopki za zdravljenje tumorja hematopoetskega izvora
US20050112585A1 (en) * 2003-11-21 2005-05-26 Dominic Zichi Method for adjusting the quantification range of individual analytes in a multiplexed assay
EP2221315A1 (de) 2003-12-04 2010-08-25 Xencor, Inc. Verfahren zur Erzeugung von Proteinvarianten mit erhöhtem Wirtsstranginhalt und Zusammensetzungen davon
WO2005062868A2 (en) * 2003-12-19 2005-07-14 Osteotech, Inc. Tissue-derived mesh for orthopedic regeneration
US7803931B2 (en) 2004-02-12 2010-09-28 Archemix Corp. Aptamer therapeutics useful in the treatment of complement-related disorders
PT3385384T (pt) 2004-02-12 2020-06-30 Archemix Llc Terapêuticas com aptâmeros úteis no tratamento de desordens relacionadas com o complemento
US20060193821A1 (en) * 2004-03-05 2006-08-31 Diener John L Aptamers to the human IL-12 cytokine family and their use as autoimmune disease therapeutics
BRPI0508363A (pt) * 2004-03-05 2007-07-24 Archemix Corp aptámeros para a famìlia de citocinas de il-12 humana e seus usos como terapia de doença auto-imune
US7569223B2 (en) * 2004-03-22 2009-08-04 The Rockefeller University Phage-associated lytic enzymes for treatment of Streptococcus pneumoniae and related conditions
WO2005092925A2 (en) 2004-03-24 2005-10-06 Xencor, Inc. Immunoglobulin variants outside the fc region
US7785903B2 (en) * 2004-04-09 2010-08-31 Genentech, Inc. Variable domain library and uses
US20080214489A1 (en) * 2004-04-19 2008-09-04 Anthony Dominic Keefe Aptamer-mediated intracellular delivery of oligonucleotides
WO2005106042A2 (en) 2004-04-22 2005-11-10 Regado Biosciences, Inc. Improved modulators of coagulation factors
US7579450B2 (en) 2004-04-26 2009-08-25 Archemix Corp. Nucleic acid ligands specific to immunoglobulin E and their use as atopic disease therapeutics
WO2005106012A2 (en) 2004-04-28 2005-11-10 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with dipeptidyl-peptidase 1 (dpp1)
WO2005118647A2 (en) * 2004-05-18 2005-12-15 Genentech, Inc. M13 virus major coat protein variants for c-terminal and bi-terminal display of a heterologous protein
CA2570872A1 (en) 2004-06-16 2006-01-26 Diversa Corporation Compositions and methods for enzymatic decolorization of chlorophyll
KR20070101227A (ko) 2004-09-07 2007-10-16 아케믹스 코포레이션 폰 빌레브란트 인자에 대한 앱타머 및 이의 혈전증치료제로서의 용도
CA2578046A1 (en) * 2004-09-07 2006-03-16 Archemix Corp. Aptamer medicinal chemistry
US7566701B2 (en) * 2004-09-07 2009-07-28 Archemix Corp. Aptamers to von Willebrand Factor and their use as thrombotic disease therapeutics
GB0422052D0 (en) 2004-10-04 2004-11-03 Dansico As Enzymes
GB0423139D0 (en) 2004-10-18 2004-11-17 Danisco Enzymes
US9200079B2 (en) 2004-11-12 2015-12-01 Xencor, Inc. Fc variants with altered binding to FcRn
ES2323651T3 (es) * 2005-01-05 2009-07-22 F-Star Biotechnologische Forschungs- Und Entwicklungsges.M.B.H. Dominios sinteticos de inmunoglobulina con propiedades de union elaborados por ingenieria en regiones de la molecula diferentes de las regiones que determinan la complementariedad.
PA8660701A1 (es) 2005-02-04 2006-09-22 Pfizer Prod Inc Agonistas de pyy y sus usos
EP2192132A3 (de) 2005-02-08 2010-08-18 ZymoGenetics, Inc. Anti-il-20-, Anti-il-22- und Anti-il-22ra-Antikörper und Bindungspartner sowie Verwendungsverfahren bei Entzündungen
EP1869174B1 (de) 2005-03-10 2015-02-18 BASF Enzymes LLC Lyase-enzyme, nukleinsäuren zu deren kodierung und verfahren zu deren herstellung und verwendung
CA2597325A1 (en) 2005-03-10 2006-09-21 Genentech, Inc. Methods and compositions for modulating vascular integrity
CA2861310A1 (en) 2005-03-15 2006-09-28 Bp Corporation North America Inc. Cellulases, nucleic acids encoding them and methods for making and using them
PA8672101A1 (es) 2005-04-29 2006-12-07 Centocor Inc Anticuerpos anti-il-6, composiciones, métodos y usos
EP3683230A1 (de) 2005-05-12 2020-07-22 ZymoGenetics, Inc. Zusammensetzungen und verfahren zur modulation von immunsystemreaktionen
US20060271262A1 (en) * 2005-05-24 2006-11-30 Mclain Harry P Iii Wireless agricultural network
US8389469B2 (en) * 2005-06-06 2013-03-05 The Rockefeller University Bacteriophage lysins for Bacillus anthracis
DK2452694T3 (en) 2005-06-30 2019-03-04 Janssen Biotech Inc Anti-IL-23 antibodies, compositions, methods and applications
CN101379085B (zh) * 2005-06-30 2013-03-27 Abbvie公司 Il-12/p40结合蛋白
US7582291B2 (en) * 2005-06-30 2009-09-01 The Rockefeller University Bacteriophage lysins for Enterococcus faecalis, Enterococcus faecium and other bacteria
EP1928506A4 (de) 2005-08-19 2009-10-21 Abbott Lab Doppel-variabel-domänen-immunglobulin und seine verwendungen
US7612181B2 (en) * 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
EP2500357A3 (de) 2005-08-19 2012-10-24 Abbott Laboratories Immunglobuline mit zweifacher variabler Domäne und ihre Verwendung
US20090215992A1 (en) * 2005-08-19 2009-08-27 Chengbin Wu Dual variable domain immunoglobulin and uses thereof
EP2360248A1 (de) 2005-08-24 2011-08-24 The Rockefeller University PLY-GBS-mutante Lysine
WO2007035527A2 (en) 2005-09-15 2007-03-29 Duke University Non-fouling polymeric surface modification and signal amplification method for biomolecular detection
ES2542501T3 (es) * 2005-09-30 2015-08-06 Abbvie Deutschland Gmbh & Co Kg Dominios de unión de proteínas de la familia de proteínas de moléculas de orientación repulsiva (RGM) y fragmentos funcionales de las mismas, así como su uso
US8679490B2 (en) 2005-11-07 2014-03-25 Genentech, Inc. Binding polypeptides with diversified and consensus VH/VL hypervariable sequences
GB2432366B (en) * 2005-11-19 2007-11-21 Alligator Bioscience Ab A method for in vitro molecular evolution of protein function
ES2453941T5 (es) 2005-11-30 2017-05-31 Abbvie Inc. Anticuerpos monoclonales contra la proteína beta amiloide y usos de los mismos
US8691224B2 (en) * 2005-11-30 2014-04-08 Abbvie Inc. Anti-Aβ globulomer 5F7 antibodies
EP1973951A2 (de) * 2005-12-02 2008-10-01 Genentech, Inc. Bindende polypeptide mit eingeschränkten diversitätssequenzen
MY163032A (en) 2005-12-29 2017-07-31 Centocor Inc Human anti-il-23 antibodies, compositions, methods and uses
US20090324574A1 (en) 2006-02-02 2009-12-31 Verenium Corporation Esterases and Related Nucleic Acids and Methods
WO2007092313A2 (en) * 2006-02-03 2007-08-16 Indiana University Research And Technology Corporation Construction of open reading frame libraries and protein structures
MY160770A (en) 2006-02-10 2017-03-15 Verenium Corp Cellulolytic enzymes, nucleic acids encoding them and methods for making and using them
BRPI0707784B1 (pt) 2006-02-14 2018-05-22 Verenium Corporation Ácido nucléico isolado, sintético ou recombinante, cassete de expressão, vetor ou veículo de clonagem, célula hospedeira isolada transformada, e método para produção de um polipeptídeo recombinante
US8043837B2 (en) 2006-03-07 2011-10-25 Cargill, Incorporated Aldolases, nucleic acids encoding them and methods for making and using them
EP2388316A3 (de) 2006-03-07 2012-03-14 Verenium Corporation Adolasen, Nukleinsäuren, die diese codieren, und Verfahren zu deren Herstellung und Verwendung
RU2477137C2 (ru) * 2006-03-08 2013-03-10 АРКЕМИКС Эл Эл Си Связывающие комплемент аптамеры и средства против с5, пригодные для лечения глазных нарушений
WO2007126455A2 (en) 2006-04-05 2007-11-08 Genentech, Inc. Method for using boc/cdo to modulate hedgehog signaling
EP2016101A2 (de) * 2006-05-09 2009-01-21 Genentech, Inc. Bindung von polypeptiden mit optimierten gerüsten
AT503889B1 (de) * 2006-07-05 2011-12-15 Star Biotechnologische Forschungs Und Entwicklungsges M B H F Multivalente immunglobuline
AT503902B1 (de) 2006-07-05 2008-06-15 F Star Biotech Forsch & Entw Verfahren zur manipulation von immunglobulinen
AT503861B1 (de) 2006-07-05 2008-06-15 F Star Biotech Forsch & Entw Verfahren zur manipulation von t-zell-rezeptoren
WO2008012629A2 (en) 2006-07-24 2008-01-31 Biorexis Pharmaceutical Corporation Exendin fusion proteins
US20110117067A1 (en) 2006-08-04 2011-05-19 Verenium Corporation Glucanases, Nucleic Acids Encoding Them and Methods for Making and Using Them
US8586006B2 (en) 2006-08-09 2013-11-19 Institute For Systems Biology Organ-specific proteins and methods of their use
CN101512008B (zh) 2006-09-08 2015-04-01 艾伯维巴哈马有限公司 白介素-13结合蛋白
EP2083017A4 (de) 2006-09-14 2011-01-12 Med & Biological Lab Co Ltd Antikörper mit verbesserter adcc-wirkung und verfahren zu dessen herstellung
DK2617823T3 (da) 2006-09-21 2015-10-05 Basf Enzymes Llc Phytaser, nukleinsyrer, der koder for disse, og fremgangsmåde til fremstilling og anvendelse heraf
ES2451266T3 (es) 2006-09-21 2014-03-26 Dsm Ip Assets B.V. Fosfolipasas, ácidos nucleicos que las codifican, y métodos para obtenerlas y usarlas
US9382327B2 (en) * 2006-10-10 2016-07-05 Vaccinex, Inc. Anti-CD20 antibodies and methods of use
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
EP2479266B1 (de) 2006-12-21 2016-03-09 BASF Enzymes LLC Amylasen und Glucoamylasen, dafür kodierende Nukleinsäuren sowie Verfahren zu ihrer Herstellung und Verwendung
US7964356B2 (en) 2007-01-16 2011-06-21 Somalogic, Inc. Method for generating aptamers with improved off-rates
US7855054B2 (en) 2007-01-16 2010-12-21 Somalogic, Inc. Multiplexed analyses of test samples
US8975026B2 (en) 2007-01-16 2015-03-10 Somalogic, Inc. Method for generating aptamers with improved off-rates
US7947447B2 (en) 2007-01-16 2011-05-24 Somalogic, Inc. Method for generating aptamers with improved off-rates
US20110136099A1 (en) 2007-01-16 2011-06-09 Somalogic, Inc. Multiplexed Analyses of Test Samples
CA2675366A1 (en) * 2007-01-18 2008-07-24 University Of Southern California Gene polymorphisms predictive for dual tki therapy
CA2674721C (en) 2007-01-30 2018-04-03 Verenium Corporation Enzymes for the treatment of lignocellulosics, nucleic acids encoding them and methods for making and using them
US8143046B2 (en) 2007-02-07 2012-03-27 Danisco Us Inc., Genencor Division Variant Buttiauxella sp. phytases having altered properties
AU2008218925A1 (en) * 2007-02-20 2008-08-28 Anaptysbio, Inc. Somatic hypermutation systems
US7875431B2 (en) 2007-02-22 2011-01-25 Genentech, Inc. Methods for detecting inflammatory bowel disease
EP2124952A2 (de) * 2007-02-27 2009-12-02 Abbott GmbH & Co. KG Verfahren zur behandlung von amyloidosen
US20090232801A1 (en) * 2007-05-30 2009-09-17 Abbot Laboratories Humanized Antibodies Which Bind To AB (1-42) Globulomer And Uses Thereof
PE20090329A1 (es) * 2007-05-30 2009-03-27 Abbott Lab Anticuerpos humanizados contra el globulomero ab(20-42) y sus usos
US20090203766A1 (en) * 2007-06-01 2009-08-13 Archemix Corp. vWF aptamer formulations and methods for use
ES2975748T3 (es) 2007-06-26 2024-07-12 F Star Therapeutics Ltd Presentación de agentes de unión
EP4056711A1 (de) 2007-07-17 2022-09-14 SomaLogic Operating Co., Inc. Verfahren zur herstellung von aptameren mit verringerten ausfallraten
EP2033971A1 (de) * 2007-09-06 2009-03-11 Abbott GmbH & Co. KG Bone Morphogenetic Protein (BMP)-bindende Domänen von Proteinen der Repulsive Guidance Molecule (RGM) Proteinfamilie und funktionale Fragmente davon sowie deren Verwendung
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
US8691730B2 (en) 2007-09-14 2014-04-08 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
CA2697583C (en) 2007-09-28 2016-04-12 Portola Pharmaceuticals, Inc. Antidotes for factor xa inhibitors and methods of using the same
NZ584967A (en) 2007-10-03 2012-08-31 Verenium Corp Xylanases, nucleic acids encoding them and methods for making and using them
US8957031B2 (en) * 2007-10-23 2015-02-17 Regents Of The University Of Colorado, A Body Corporate Competitive inhibitors of invariant chain expression and/or ectopic clip binding
WO2009055656A2 (en) 2007-10-26 2009-04-30 Centocor, Inc. Vectors, host cells, and methods of production and uses
US8906700B2 (en) 2007-11-06 2014-12-09 Ambergen, Inc. Methods and compositions for phototransfer
US9102711B2 (en) * 2007-12-31 2015-08-11 Xoma Technology Ltd. Methods and materials for targeted mutagenesis
WO2009088753A1 (en) 2008-01-03 2009-07-16 Verenium Corporation Isomerases, nucleic acids encoding them and methods for making and using them
EP2238242B9 (de) 2008-01-03 2015-06-10 BASF Enzymes LLC Transferasen und oxidoreduktasen, dafür kodierende nukleinsäuren sowie verfahren zu ihrer herstellung und verwendung
US7682809B2 (en) 2008-01-11 2010-03-23 Agilent Technologies, Inc. Direct ATP release sequencing
US8962803B2 (en) 2008-02-29 2015-02-24 AbbVie Deutschland GmbH & Co. KG Antibodies against the RGM A protein and uses thereof
US9873957B2 (en) 2008-03-13 2018-01-23 Dyax Corp. Libraries of genetic packages comprising novel HC CDR3 designs
DK2281078T3 (en) * 2008-04-24 2015-02-02 Dyax Corp LIBRARIES OF RE-PACKAGES INCLUDING UNKNOWN HC-CDR1, -CDR2 AND -CDR3 AND UNKNOWN LC-CDR1, -CDR2 AND-CDR3 DESIGNS
SG190572A1 (en) 2008-04-29 2013-06-28 Abbott Lab Dual variable domain immunoglobulins and uses thereof
US20100260668A1 (en) * 2008-04-29 2010-10-14 Abbott Laboratories Dual Variable Domain Immunoglobulins and Uses Thereof
WO2009133462A2 (en) 2008-04-30 2009-11-05 Danisco A/S Proteins
EP2113255A1 (de) 2008-05-02 2009-11-04 f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. Zytotoxisches Immunglobulin
CN104558178A (zh) 2008-05-09 2015-04-29 Abbvie公司 针对渐进性糖化终极产物受体（rage）的抗体及其用途
UY31861A (es) * 2008-06-03 2010-01-05 Abbott Lab Inmunoglobulina con dominio variable dual y usos de la misma
SG191639A1 (en) * 2008-06-03 2013-07-31 Abbott Lab Dual variable domain immunoglobulins and uses thereof
CA2728308A1 (en) 2008-06-20 2009-12-23 Wyeth Llc Compositions and methods of use of orf1358 from beta-hemolytic streptococcal strains
US8575314B2 (en) * 2008-06-20 2013-11-05 National University Corporation Okayama University Antibody against oxidized LDL/β2GPI complex and use of the same
TW201014602A (en) 2008-07-08 2010-04-16 Abbott Lab Prostaglandin E2 binding proteins and uses thereof
BRPI0915448A2 (pt) * 2008-07-08 2015-11-10 Abbott Lab imunoglobulinas de domínio variável duplo para prostaglandina e2 e usos das mesmas
US8703416B2 (en) 2008-07-17 2014-04-22 Somalogic, Inc. Method for purification and identification of sperm cells
AU2009274568A1 (en) * 2008-07-25 2010-01-28 The Regents Of The University Of Colorado Proteins for use in diagnosing and treating infection and disease
US20100166782A1 (en) * 2008-07-25 2010-07-01 Martha Karen Newell Clip inhibitors and methods of modulating immune function
US9182406B2 (en) * 2008-08-04 2015-11-10 Biodesy, Inc. Nonlinear optical detection of molecules comprising an unnatural amino acid possessing a hyperpolarizability
CA2733642A1 (en) 2008-08-14 2010-02-18 Cephalon Australia Pty Ltd Anti-il-12/il-23 antibodies
US8153391B2 (en) 2008-08-29 2012-04-10 Bunge Oils, Inc. Hydrolases, nucleic acids encoding them and methods for making and using them
US8357503B2 (en) 2008-08-29 2013-01-22 Bunge Oils, Inc. Hydrolases, nucleic acids encoding them and methods for making and using them
US8198062B2 (en) 2008-08-29 2012-06-12 Dsm Ip Assets B.V. Hydrolases, nucleic acids encoding them and methods for making and using them
EP2360172B1 (de) 2008-10-20 2017-10-18 Gwangju Institute of Science and Technology Bipodaler peptidbinder
SG171812A1 (en) * 2008-12-04 2011-07-28 Abbott Lab Dual variable domain immunoglobulins and uses thereof
US8492133B2 (en) 2009-01-20 2013-07-23 Ramot At Tel Aviv University, Ltd. MIR-21 promoter driven targeted cancer therapy
JP2012516153A (ja) * 2009-01-29 2012-07-19 アボット・ラボラトリーズ Ｉｌ−１結合タンパク質
US20110165063A1 (en) * 2009-01-29 2011-07-07 Abbott Laboratories Il-1 binding proteins
US8030026B2 (en) 2009-02-24 2011-10-04 Abbott Laboratories Antibodies to troponin I and methods of use thereof
KR101579771B1 (ko) 2009-03-05 2015-12-28 애브비 인코포레이티드 Ｉｌ-17 결합 단백질
EP2414517B1 (de) 2009-03-30 2016-09-21 Portola Pharmaceuticals, Inc. Gegenmittel für faktor-xa-hemmer und verwendungsverfahren dafür
GB0908770D0 (en) 2009-04-24 2009-07-01 Danisco Method
US9695403B2 (en) 2009-05-21 2017-07-04 Syngenta Participations Ag Phytases, nucleic acids encoding them and methods for making and using them
JP6163304B2 (ja) 2009-07-15 2017-07-12 ポートラ ファーマシューティカルズ， インコーポレイテッド 第Ｘａ因子インヒビターの解毒剤の単位用量処方物およびその使用方法
UY32808A (es) * 2009-07-29 2011-02-28 Abbott Lab Inmunoglobulinas como dominio variable dual y usos de las mismas
MX2012002605A (es) 2009-08-29 2012-04-02 Abbott Lab Proteinas terapeutico de union a dll4.
MX2012002651A (es) 2009-09-01 2012-05-22 Abbott Lab Inmunoglobulinas de dominio variable doble y usos de las mismas.
AU2010291902A1 (en) * 2009-09-14 2012-04-05 Dyax Corp. Libraries of genetic packages comprising novel HC CDR3 designs
EP3187877A1 (de) 2009-09-25 2017-07-05 XOMA Technology Ltd. Screening-verfahren
US8926976B2 (en) 2009-09-25 2015-01-06 Xoma Technology Ltd. Modulators
WO2011047262A2 (en) 2009-10-15 2011-04-21 Abbott Laboratories Dual variable domain immunoglobulins and uses thereof
UA111708C2 (uk) 2009-10-16 2016-06-10 Бандж Ойлз, Інк. Спосіб рафінування олії
UA109884C2 (uk) 2009-10-16 2015-10-26 Поліпептид, що має активність ферменту фосфатидилінозитол-специфічної фосфоліпази с, нуклеїнова кислота, що його кодує, та спосіб його виробництва і застосування
WO2011050194A1 (en) 2009-10-22 2011-04-28 Genentech, Inc. Methods and compositions for modulating hepsin activation of macrophage-stimulating protein
UY32979A (es) * 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
TW201121568A (en) * 2009-10-31 2011-07-01 Abbott Lab Antibodies to receptor for advanced glycation end products (RAGE) and uses thereof
PE20121584A1 (es) 2009-11-30 2012-11-29 Genentech Inc Composiciones y metodos para el diagnostico y el tratamiento de tumores
ES2562832T3 (es) * 2009-12-08 2016-03-08 Abbvie Deutschland Gmbh & Co Kg Anticuerpos monoclonales contra la proteína RGM para su uso en el tratamiento de la degeneración de la capa de fibra nerviosa de la retina
CN105001334A (zh) 2010-02-10 2015-10-28 伊缪诺金公司 Cd20抗体及其用途
PL2536748T3 (pl) 2010-02-18 2015-01-30 Genentech Inc Antagoniści neureguliny i ich zastosowanie w leczeniu nowotworu
EP2538981B1 (de) 2010-02-23 2017-12-20 F. Hoffmann-La Roche AG Zusammensetzungen und methoden zur diagnose und behandlung von tumoren
DK2538976T3 (en) 2010-02-24 2017-02-27 Immunogen Inc IMMUNCONJUGATES AGAINST FOLATRECEPTOR-1 AND APPLICATIONS THEREOF
PE20130580A1 (es) 2010-03-02 2013-06-02 Abbvie Inc Proteinas terapeuticas de union a dll4
WO2011109642A1 (en) 2010-03-03 2011-09-09 Somalogic, Inc. Aptamers to 4-1bb and their use in treating diseases and disorders
CA2795043C (en) 2010-03-30 2019-04-23 Janssen Biotech, Inc. Humanized il-25 antibodies
CA2797188C (en) 2010-04-12 2020-03-31 Somalogic, Inc. 5-position modified pyrimidines and their use
US8987419B2 (en) 2010-04-15 2015-03-24 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
WO2011139985A1 (en) 2010-05-03 2011-11-10 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
EP2571532B1 (de) 2010-05-14 2017-05-03 Abbvie Inc. Il-1-bindende proteine
US20120009196A1 (en) 2010-07-08 2012-01-12 Abbott Laboratories Monoclonal antibodies against hepatitis c virus core protein
GB201011513D0 (en) 2010-07-08 2010-08-25 Danisco Method
UY33492A (es) 2010-07-09 2012-01-31 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
DK3336225T3 (da) 2010-07-16 2020-03-30 Adimab Llc Antistofbiblioteker
PE20131412A1 (es) 2010-08-03 2014-01-19 Abbvie Inc Inmunoglobulinas con dominio variable dual y usos de las mismas
CA2808187A1 (en) 2010-08-14 2012-02-23 Abbvie Inc. Amyloid-beta binding proteins
ES2665954T3 (es) 2010-08-19 2018-04-30 Zoetis Belgium S.A. Anticuerpos anti-NGF y su uso
TW201211252A (en) 2010-08-26 2012-03-16 Abbott Lab Dual variable domain immunoglobulins and uses thereof
AR083354A1 (es) 2010-10-06 2013-02-21 Bp Corp North America Inc Polipeptidos variantes cbh i (celobiohidrolasas i) con reducida inhibicion de producto
CA2821976A1 (en) 2010-12-21 2012-09-13 Abbvie Inc. Il-1 -alpha and -beta bispecific dual variable domain immunoglobulins and their use
US20120275996A1 (en) 2010-12-21 2012-11-01 Abbott Laboratories IL-1 Binding Proteins
CN103620032B (zh) 2010-12-31 2016-02-24 生物蛋白有限公司 抗体的快速人源化
AU2012230899A1 (en) 2011-03-21 2013-10-10 Biodesy, Llc Classification of kinase inhibitors using nonlinear optical techniques
CN107189997A (zh) 2011-04-21 2017-09-22 洛克菲勒大学 用于革兰氏阳性菌检测和治疗的链球菌属细菌噬菌体溶素
EP2734236A4 (de) 2011-07-13 2015-04-15 Abbvie Inc Verfahren und zusammensetzungen zur behandlung von asthma mit anti-il-13-antikörpern
WO2013016449A2 (en) 2011-07-26 2013-01-31 Indicator Systems International, Inc. Assays for the detection of microbes
JP2014533927A (ja) 2011-09-15 2014-12-18 ジェネンテック， インコーポレイテッド 分化を促進する方法
CN104114695B (zh) 2011-10-05 2018-04-17 洛克菲勒大学 二聚噬菌体溶素
JP6254087B2 (ja) 2011-10-15 2017-12-27 ジェネンテック， インコーポレイテッド 癌を治療するためのｓｃｄ１アンタゴニスト
RU2014120981A (ru) 2011-10-24 2015-12-10 Эббви Инк. Иммунные связывающие агенты против склеростина
CN104093743B (zh) 2011-11-23 2018-04-24 医学免疫有限责任公司 特异于her3的结合分子及其用途
JP6336397B2 (ja) 2011-12-14 2018-06-06 アッヴィ・ドイチュラント・ゲー・エム・ベー・ハー・ウント・コー・カー・ゲー 鉄関連障害を診断および治療するための組成物および方法
WO2013090635A2 (en) 2011-12-14 2013-06-20 AbbVie Deutschland GmbH & Co. KG Composition and method for the diagnosis and treatment of iron-related disorders
AR089529A1 (es) 2011-12-30 2014-08-27 Abbvie Inc Proteinas de union especificas duales dirigidas contra il-13 y/o il-17
CA2862424A1 (en) 2012-01-18 2013-07-25 Genentech, Inc. Methods of using fgf19 modulators
MX359854B (es) 2012-01-20 2018-10-12 Genzyme Corp Anticuerpos anti-cxcr3.
BR112014018592B1 (pt) 2012-01-27 2022-03-15 Abbvie Inc. Anticorpo monoclonal isolado que se liga à molécula de orientação repulsiva a (rgma)
US20130209473A1 (en) 2012-02-11 2013-08-15 Genentech, Inc. R-spondin translocations and methods using the same
JP6181089B2 (ja) 2012-03-08 2017-08-16 ハロザイム インコーポレイテッド 条件依存活性抗上皮細胞増殖因子受容体抗体およびその使用方法
WO2013136193A2 (en) 2012-03-16 2013-09-19 University Health Network Methods and compositions for modulating toso activity
US9139863B2 (en) 2012-03-16 2015-09-22 Genentech, Inc. Engineered conformationally-stabilized proteins
KR20140142293A (ko) 2012-03-16 2014-12-11 제넨테크, 인크. 조작된 입체형태적으로-안정화된 단백질
MX2014010953A (es) 2012-03-16 2014-10-13 Hoffmann La Roche Metodos para tratamiento de melanoma con inhibidores pak1.
US9592289B2 (en) 2012-03-26 2017-03-14 Sanofi Stable IgG4 based binding agent formulations
EP2841951B1 (de) 2012-04-25 2019-12-11 Biodesy, Inc. Verfahren zum nachweis von allosterischen proteinmodulatoren
WO2013170191A1 (en) 2012-05-11 2013-11-14 Genentech, Inc. Methods of using antagonists of nad biosynthesis from nicotinamide
MX369626B (es) 2012-05-24 2019-11-13 Mountgate Group Ltd Composiciones y metodos relacionados con la prevencion y el tratamiento de infecciones por rabia.
CN104364264B (zh) 2012-06-06 2018-07-24 硕腾服务有限责任公司 犬源化抗ngf抗体和其方法
UY34905A (es) 2012-07-12 2014-01-31 Abbvie Inc Proteínas de unión a il-1
CN104755498B (zh) 2012-08-31 2019-06-18 伊缪诺金公司 用于检测叶酸受体1的诊断测定和试剂盒
TW202037609A (zh) 2012-11-01 2020-10-16 美商艾伯維有限公司 抗-vegf/dll4雙重可變區域免疫球蛋白及其用途
US9550986B2 (en) 2012-12-21 2017-01-24 Abbvie Inc. High-throughput antibody humanization
CA2900097A1 (en) 2013-02-22 2014-08-28 F. Hoffmann-La Roche Ag Methods of treating cancer and preventing drug resistance
EP2964260A2 (de) 2013-03-06 2016-01-13 F. Hoffmann-La Roche AG Verfahren zur behandlung und prävention einer antikrebsmittelresistenz
GB201308828D0 (en) 2013-03-12 2013-07-03 Verenium Corp Phytase
JP2016516046A (ja) 2013-03-14 2016-06-02 ジェネンテック， インコーポレイテッド がんの治療方法及びがん薬物耐性を阻止する方法
WO2014143343A1 (en) 2013-03-14 2014-09-18 Abbott Laboratories Hcv core lipid binding domain monoclonal antibodies
GB201308843D0 (en) 2013-03-14 2013-07-03 Verenium Corp Phytase formulation
BR112015023355A8 (pt) 2013-03-14 2018-01-30 Abbott Lab antígenos recombinantes ns3 de hcv e mutantes dos mesmos para detecção de anticorpos aprimorada.
WO2014158272A1 (en) 2013-03-14 2014-10-02 Abbott Laboratories Hcv antigen-antibody combination assay and methods and compositions for use therein
WO2014144280A2 (en) 2013-03-15 2014-09-18 Abbvie Inc. DUAL SPECIFIC BINDING PROTEINS DIRECTED AGAINST IL-1β AND / OR IL-17
WO2014150914A2 (en) 2013-03-15 2014-09-25 Pioneer Hi-Bred International, Inc. Phi-4 polypeptides and methods for their use
BR112015023203A8 (pt) 2013-03-15 2018-01-23 Constellation Pharmaceuticals Inc métodos para tratamento de câncer, método para aumentar a eficiência de um tratamento de câncer, método para retardar e/ou prevenir o desenvolvimento de câncer, método para tratar um indivíduo com câncer, método para aumentar a sensibilidade para um agente de terapia para câncer, método para estender um período de sensibilidade e método para estender a duração da resposta para uma terapia para câncer.
KR20230070054A (ko) 2013-03-15 2023-05-19 제넨테크, 인크. Pd-1 및 pd-l1 관련 상태를 치료하기 위한 바이오마커 및 방법
US9469686B2 (en) 2013-03-15 2016-10-18 Abbott Laboratories Anti-GP73 monoclonal antibodies and methods of obtaining the same
CA2914566A1 (en) 2013-06-07 2014-12-11 Duke University Inhibitors of complement factor h
KR20160033711A (ko) 2013-07-25 2016-03-28 바스프 엔자임스 엘엘씨 피타아제
MX359026B (es) 2013-08-16 2018-09-12 Pioneer Hi Bred Int Proteinas insecticidas y metodos de uso.
EP3925980A1 (de) 2013-08-30 2021-12-22 ImmunoGen, Inc. Antikörper und tests zum nachweis von folatrezeptor 1
MX2016003256A (es) 2013-09-12 2016-06-07 Halozyme Inc Anticuerpos modificados del receptor de factor de crecimiento anti-epidermico y metodos de uso de los mismos.
MX359027B (es) 2013-09-13 2018-09-12 Pioneer Hi Bred Int Proteinas insecticidas y metodos para su uso.
CN114163529A (zh) 2013-12-24 2022-03-11 杨森制药公司 抗vista抗体及片段
WO2015116902A1 (en) 2014-01-31 2015-08-06 Genentech, Inc. G-protein coupled receptors in hedgehog signaling
UA120608C2 (uk) 2014-02-07 2020-01-10 Піонір Хай-Бред Інтернешнл, Інк. Очищений поліпептид ptip-83 та спосіб його застосування
CA2938979C (en) 2014-02-07 2024-02-20 Pioneer Hi-Bred International, Inc. Insecticidal proteins and methods for their use
EP3113798B1 (de) 2014-03-07 2019-06-05 University Health Network Verfahren und zusammensetzungen zur modifikation der immunantwort
CA2948275C (en) 2014-04-08 2023-10-17 Boston Pharmaceuticals Inc. Binding molecules specific for il-21 and uses thereof
BR112016022910A2 (pt) 2014-04-11 2017-10-17 Medimmune Llc anticorpos contra her2 biespecíficos
GB201406767D0 (en) 2014-04-15 2014-05-28 Cancer Rec Tech Ltd Humanized anti-Tn-MUC1 antibodies anf their conjugates
CA3225091A1 (en) 2014-05-05 2015-11-12 Regeneron Pharmaceuticals, Inc. Humanized c5 and c3 animals
WO2015179835A2 (en) 2014-05-23 2015-11-26 Genentech, Inc. Mit biomarkers and methods using the same
EP3154589A1 (de) 2014-06-13 2017-04-19 Genentech, Inc. Verfahren zur behandlung und prävention der antikrebsmittelresistenz
EP3157945A4 (de) 2014-06-20 2017-11-22 F. Hoffmann-La Roche AG Chagasinbasierten gerüstzusammensetzungen, verfahren und verwendungen
BR112017007932A2 (pt) 2014-10-16 2018-01-23 Du Pont proteínas inseticidas e métodos para uso das mesmas
DK3209773T3 (da) 2014-10-24 2020-06-15 Dupont Nutrition Biosci Aps Prolintolerante tripeptidylpeptidaser og anvendelser deraf
BR112017007949A2 (pt) 2014-10-24 2018-01-23 Danisco Us Inc método para produção de álcool pelo uso de uma tripeptidil-peptidase
RS62003B1 (sr) 2014-11-10 2021-07-30 Medimmune Ltd Vezujući molekuli specifični za cd73 i njihove upotrebe
EP3789403A1 (de) 2014-11-11 2021-03-10 MedImmune Limited Therapeutische kombinationen mit anti-cd73-antikörpern und a2a-rezeptorinhibitoren sowie verwendungen davon
WO2016094881A2 (en) 2014-12-11 2016-06-16 Abbvie Inc. Lrp-8 binding proteins
WO2016106286A1 (en) 2014-12-23 2016-06-30 Biodesy, Inc. Attachment of proteins to interfaces for use in nonlinear optical detection
AU2016206682B2 (en) 2015-01-14 2021-11-11 The Brigham And Women's Hospital, Inc. Treatment of cancer with anti-LAP monoclonal antibodies
EA038923B1 (ru) 2015-03-11 2021-11-10 Пайонир Хай-Бред Интернэшнл, Инк. Инсектицидная днк-конструкция и способы её применения
EP3286227A2 (de) 2015-04-24 2018-02-28 F. Hoffmann-La Roche AG Multispezifische antigenbindende proteine
CA2985198A1 (en) 2015-05-19 2016-11-24 Pioneer Hi-Bred International, Inc. Insecticidal proteins and methods for their use
WO2016196314A1 (en) 2015-05-29 2016-12-08 Abbvie Inc. Anti-cd40 antibodies and uses thereof
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
BR112017027870A2 (pt) 2015-06-24 2018-08-28 Janssen Pharmaceutica Nv anticorpos e fragmentos anti-vista
WO2016210395A1 (en) 2015-06-26 2016-12-29 Dupont Nutrition Biosciences Aps Aminopeptidases for protein hydrlyzates
US10077313B2 (en) 2015-06-29 2018-09-18 Immunogen, Inc. Anti-CD123 antibodies and conjugates and derivatives thereof
WO2017011275A1 (en) 2015-07-10 2017-01-19 Nersissian Aram M Factor viii protein compositions and methods of treating hemophilia a
EP3328429A4 (de) 2015-07-31 2019-03-20 The Research Institute at Nationwide Children's Hospital Peptide und antikörper zur beseitigung von biofilmen
UA124495C2 (uk) 2015-08-06 2021-09-29 Піонір Хай-Бред Інтернешнл, Інк. Інсектицидний білок рослинного походження та спосіб його застосування
WO2017066719A2 (en) 2015-10-14 2017-04-20 Research Institute At Nationwide Children's Hospital Hu specific interfering agents
SG11201803068YA (en) 2015-11-10 2018-05-30 Medimmune Llc Binding molecules specific for asct2 and uses thereof
CN108575091A (zh) 2015-12-18 2018-09-25 先锋国际良种公司 杀昆虫蛋白及其使用方法
US11135221B2 (en) 2015-12-23 2021-10-05 Moonshot Pharma Llc Methods for inducing an immune response
CA3014013A1 (en) 2016-02-12 2017-08-17 Janssen Pharmaceutica Nv Anti-vista (b7h5) antibodies
CA3013383A1 (en) 2016-02-25 2017-08-31 Dupont Nutrition Biosciences Aps Method for producing a protein hydrolysate employing an aspergillus fumigatus tripeptidyl peptidase
US10307455B2 (en) 2016-03-10 2019-06-04 Acceleron Pharma Inc. Activin type 2 receptor antibodies
WO2017161206A1 (en) 2016-03-16 2017-09-21 Halozyme, Inc. Conjugates containing conditionally active antibodies or antigen-binding fragments thereof, and methods of use
US10765724B2 (en) 2016-03-29 2020-09-08 Janssen Biotech, Inc. Method of treating psoriasis with increased interval dosing of anti-IL12/23 antibody
WO2017175058A1 (en) 2016-04-07 2017-10-12 Janssen Pharmaceutica Nv Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
US11390669B2 (en) 2016-04-27 2022-07-19 Abbvie, Inc. Methods of treatment of diseases in which IL-13 activity is detrimental using anti-IL-13 antibodies
US11008585B2 (en) 2016-05-04 2021-05-18 Pioneer Hi-Bred International, Inc. Insecticidal proteins and methods for their use
EP3464318B1 (de) 2016-06-02 2021-04-21 AbbVie Inc. Glucocorticoid-rezeptoragonist und immunkonjugate davon
CN109641962A (zh) 2016-06-08 2019-04-16 艾伯维公司 抗b7-h3抗体和抗体药物偶联物
EP3468993A1 (de) 2016-06-08 2019-04-17 AbbVie Inc. Anti-b7-h3-antikörper und antikörperarzneimittelkonjugate
TW202304996A (zh) 2016-06-08 2023-02-01 美商艾伯維有限公司 抗-b7-h3抗體及抗體藥物結合物
GB201610198D0 (en) 2016-06-10 2016-07-27 Ucb Biopharma Sprl Anti-ige antibodies
US20190330641A1 (en) 2016-06-17 2019-10-31 National Hellenic Research Foundation Systems for recombinant protein production
MX2018015906A (es) 2016-07-01 2019-04-04 Pioneer Hi Bred Int Proteinas insecticidas de plantas y metodos para sus usos.
WO2018049275A1 (en) 2016-09-09 2018-03-15 Genentech, Inc. Selective peptide inhibitors of frizzled
MX2019003703A (es) 2016-09-30 2020-08-13 Janssen Biotech Inc Método seguro y eficaz para tratar la psoriasis con el anticuerpo específico anti-il23.
US20180106800A1 (en) 2016-10-03 2018-04-19 Abbott Laboratories Methods of assessing uch-l1 status in patient samples
WO2018084936A1 (en) 2016-11-01 2018-05-11 Pioneer Hi-Bred International, Inc. Insecticidal proteins and methods for their use
AU2017362222A1 (en) 2016-11-16 2019-05-30 Janssen Biotech, Inc. Method of treating psoriasis with anti-IL-23 specific antibody
WO2018098363A2 (en) 2016-11-23 2018-05-31 Bioverativ Therapeutics Inc. Bispecific antibodies binding to coagulation factor ix and coagulation factor x
US10899842B2 (en) 2016-11-23 2021-01-26 Immunoah Therapeutics, Inc. 4-1BB binding proteins and uses thereof
US11174295B2 (en) 2016-12-14 2021-11-16 Pioneer Hi-Bred International, Inc. Insecticidal proteins and methods for their use
MX2019007491A (es) 2016-12-22 2019-09-06 Pioneer Hi Bred Int Proteinas insecticidas y metodos para su uso.
WO2018129078A1 (en) 2017-01-04 2018-07-12 Research Institute At Nationwide Children's Hospital Dnabii vaccines and antibodies with enhanced activity
WO2018129092A1 (en) 2017-01-04 2018-07-12 Research Institute At Nationwide Children's Hospital Antibody fragments for the treatment of biofilm-related disorders
WO2018129029A1 (en) 2017-01-04 2018-07-12 Immunogen, Inc. Met antibodies and immunoconjugates and uses thereof
EP3565845A4 (de) 2017-01-06 2020-10-07 Biosion, Inc. Erbb2-antikörper und deren verwendungen
MX2019008989A (es) 2017-01-30 2019-10-09 Janssen Biotech Inc Anticuerpos anti-tnf, composiciones y metodos para el tratamiento de la artritis psoriasica activa.
KR20240038148A (ko) 2017-02-07 2024-03-22 얀센 바이오테크 인코포레이티드 활성 강직성 척추염의 치료를 위한 항-tnf 항체, 조성물, 및 방법
CA3052794A1 (en) 2017-02-08 2018-08-16 Pioneer Hi-Bred International, Inc. Insecticidal combinations of plant derived insecticidal proteins and methods for their use
WO2018152496A1 (en) 2017-02-17 2018-08-23 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Compositions and methods for the diagnosis and treatment of zika virus infection
IL268748B1 (en) 2017-02-27 2024-09-01 Regeneron Pharma A human model of kidney and liver disorders
EP3595445B1 (de) 2017-03-15 2024-09-04 The Research Institute at Nationwide Children's Hospital Zusammensetzung und verfahren zur brechung bakterieller biofilme ohne begleitentzündung
CA3052513A1 (en) 2017-03-23 2018-09-27 Abbott Laboratories Methods for aiding in the diagnosis and determination of the extent of traumatic brain injury in a human subject using the early biomarker ubiquitin carboxy-terminal hydrolase l1
WO2018191531A1 (en) 2017-04-15 2018-10-18 Abbott Laboratories Methods for aiding in the hyperacute diagnosis and determination of traumatic brain injury in a human subject using early biomarkers
KR20190141686A (ko) 2017-04-21 2019-12-24 제넨테크, 인크. 질환 치료를 위한 klk5 길항제의 용도
US11236151B2 (en) 2017-04-25 2022-02-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antibodies and methods for the diagnosis and treatment of Epstein Barr virus infection
CN110603449A (zh) 2017-04-28 2019-12-20 雅培实验室 用同一人受试者的至少两种样品的早期生物标记物帮助超急性诊断确定创伤性脑损伤的方法
US10865238B1 (en) 2017-05-05 2020-12-15 Duke University Complement factor H antibodies
CA3063200A1 (en) 2017-05-11 2018-11-15 Pioneer Hi-Bred International, Inc. Insecticidal proteins and methods for their use
CA3078725A1 (en) 2017-05-25 2018-11-29 Abbott Laboratories Methods for aiding in the determination of whether to perform imaging on a human subject who has sustained or may have sustained an injury to the head using early biomarkers
EP3631466A1 (de) 2017-05-30 2020-04-08 Abbott Laboratories Verfahren zur hilfe bei der diagnose und evaluierung einer leichten traumatischen hirnläsion bei einer person unter verwendung von herztroponin i und frühbiomarkern
JP2020525434A (ja) 2017-06-22 2020-08-27 ムーンショット ファーマ エルエルシー アンレキサノクス及び免疫調節剤を含む組成物で癌を治療する方法
WO2019010131A1 (en) 2017-07-03 2019-01-10 Abbott Laboratories IMPROVED METHODS FOR MEASURING CARBOXY TERMINATION HYDROLASE LEVELS OF UBIQUITIN L1 IN BLOOD
EP3655430A1 (de) 2017-07-19 2020-05-27 The U.S.A. as represented by the Secretary, Department of Health and Human Services Antikörper und verfahren zur diagnose und behandlung von hepatitis-b-virusinfektionen
CN110945023B (zh) 2017-07-31 2023-08-18 豪夫迈·罗氏有限公司 基于三维结构的人源化方法
TW201922780A (zh) 2017-09-25 2019-06-16 美商健生生物科技公司 以抗ｉｌ１２／ｉｌ２３抗體治療狼瘡之安全且有效之方法
CA3078460A1 (en) 2017-10-04 2019-04-11 Opko Pharmaceuticals, Llc Articles and methods directed to personalized therapy of cancer
EP3694552A1 (de) 2017-10-10 2020-08-19 Tilos Therapeutics, Inc. Anti-lap-antikörper und verwendungen davon
JP2021502125A (ja) 2017-11-09 2021-01-28 ピンテオン セラピューティクス インコーポレイテッド ヒト化コンホメーション特異的リン酸化タウ抗体の作製および使用のための方法および組成物
JP7344801B2 (ja) 2017-12-09 2023-09-14 アボット・ラボラトリーズ グリア原線維性酸性タンパク質（ｇｆａｐ）及び／又はユビキチンカルボキシ末端ヒドロラーゼｌ１（ｕｃｈ－ｌ１）を使用する、整形外科損傷を負っており、軽度外傷性脳損傷（ｔｂｉ）などの頭部への損傷を負ったか又は負った可能性がある対象についての診断及び査定の一助となるための方法
EP3721234A1 (de) 2017-12-09 2020-10-14 Abbott Laboratories Verfahren zur unterstützung bei der diagnose und bewertung einer traumatischen hirnverletzung beim menschen mit einer kombination aus gfap und uch-l1
US20190211098A1 (en) 2017-12-22 2019-07-11 Genentech, Inc. Use of pilra binding agents for treatment of a disease
WO2019133717A1 (en) 2017-12-29 2019-07-04 Abbott Laboratories Novel biomarkers and methods for diagnosing and evaluating traumatic brain injury
WO2019150309A1 (en) 2018-02-02 2019-08-08 Hammack Scott Modulators of gpr68 and uses thereof for treating and preventing diseases
KR20200135331A (ko) 2018-02-14 2020-12-02 비엘라 바이오, 인크. 고양이 맥도너 육종(fms)-유사 티로신 키나제 3 수용체 리간드(flt3l)에 대한 항체 및 자가면역 및 염증 질환을 치료하기 위한 이의 용도
IL310216A (en) 2018-03-05 2024-03-01 Janssen Biotech Inc Methods for treating Crohn's disease with a specific anti-IL23 antibody
CA3093772C (en) 2018-03-12 2024-04-16 Zoetis Services Llc Anti-ngf antibodies and methods thereof
BR112020018675A2 (pt) 2018-03-14 2021-01-05 Pioneer Hi-Bred International, Inc. Proteínas inseticidas de plantas e métodos para a sua utilização
CN111867377B (zh) 2018-03-14 2023-05-23 先锋国际良种公司 来自植物的杀昆虫蛋白及其使用方法
EP3788377A1 (de) 2018-05-04 2021-03-10 Abbott Laboratories Hbv-diagnostische, prognostische und therapeutische verfahren und produkte
US11708571B2 (en) 2018-05-17 2023-07-25 Bp Corporation North America Inc. Production of 2-keto-3-deoxy-d-gluconic acid in filamentous fungi
AU2019282671B2 (en) 2018-06-08 2021-05-06 Crystal Bioscience Inc. Transgenic animal for producing diversified antibodies that have the same light chain i
US20210277118A1 (en) 2018-06-21 2021-09-09 Daiichi Sankyo Company, Limited Compositions including cd3 antigen binding fragments and uses thereof
WO2020014306A1 (en) 2018-07-10 2020-01-16 Immunogen, Inc. Met antibodies and immunoconjugates and uses thereof
JP2021530697A (ja) 2018-07-18 2021-11-11 ヤンセン バイオテツク，インコーポレーテツド 抗ｉｌ２３特異的抗体で治療した後の持続応答予測因子
WO2020041360A1 (en) 2018-08-21 2020-02-27 Quidel Corporation Dbpa antibodies and uses thereof
CN113412332A (zh) 2018-09-07 2021-09-17 巴斯夫植物科学有限公司 用于在植物中产生高水平pufa的改进方法
CN112996915A (zh) 2018-09-07 2021-06-18 巴斯夫植物科学有限公司 用于在植物中产生高水平pufa的改进方法
US20230183728A1 (en) 2018-09-07 2023-06-15 Basf Plant Science Company Gmbh Improved method for the production of high levels of pufa in plants
WO2020065532A1 (en) 2018-09-24 2020-04-02 Janssen Biotech, Inc. Safe and effective method of treating ulcerative colitis with anti-il12/il23 antibody
WO2020073004A1 (en) 2018-10-05 2020-04-09 Research Institute At Nationwide Children's Hospital Compositions and methods for enzymatic disruption of bacterial biofilms
CN113164780A (zh) 2018-10-10 2021-07-23 泰洛斯治疗公司 抗lap抗体变体及其用途
US20220332800A1 (en) 2018-11-20 2022-10-20 Takeda Vaccines, Inc. Novel anti-zika virus antibodies and uses thereof
KR20210093973A (ko) 2018-11-20 2021-07-28 얀센 바이오테크 인코포레이티드 항-il23 특이적 항체로 건선을 치료하는 안전하고 효과적인 방법
WO2020128864A1 (en) 2018-12-18 2020-06-25 Janssen Biotech, Inc. Safe and effective method of treating lupus with anti-il12/il23 antibody
WO2020132557A1 (en) 2018-12-21 2020-06-25 Compass Therapeutics Llc Transgenic mouse expressing common human light chain
EP3911676A1 (de) 2019-01-15 2021-11-24 Janssen Biotech, Inc. Anti-tnf-antikörperzusammensetzungen und verfahren zur behandlung von juveniler idiopathischer arthritis
AU2020210962A1 (en) 2019-01-23 2021-07-22 Janssen Biotech, Inc. anti-TNF antibody compositions for use in methods for the treatment of Psoriatic Arthritis
KR20210141990A (ko) 2019-03-14 2021-11-23 얀센 바이오테크 인코포레이티드 항-il12/il23 항체 조성물을 생성하기 위한 제조 방법
WO2020183270A1 (en) 2019-03-14 2020-09-17 Janssen Biotech, Inc. Methods for producing anti-tnf antibody compositions
US20220153829A1 (en) 2019-03-14 2022-05-19 Janssen Biotech, Inc. Methods for Producing Anti-TNF Antibody Compositions
CA3133381A1 (en) 2019-03-14 2020-09-17 Janssen Biotech, Inc. Manufacturing methods for producing anti-tnf antibody compositions
EP3941934A4 (de) 2019-03-18 2022-12-07 Janssen Biotech, Inc. Verfahren zur behandlung von psoriasis bei kindern mit anti-il12/il23-antikörper
WO2020227554A1 (en) 2019-05-09 2020-11-12 Genentech, Inc. Methods of making antibodies
BR112021023295A2 (pt) 2019-05-23 2022-02-08 Janssen Biotech Inc Método de tratamento de doença inflamatória intestinal com uma terapia de combinação de anticorpos para il-23 e tnf-alfa
WO2020245676A1 (en) 2019-06-03 2020-12-10 Janssen Biotech, Inc. Anti-tnf antibody compositions, and methods for the treatment of psoriatic arthritis
MX2021014882A (es) 2019-06-03 2022-03-25 Janssen Biotech Inc Anticuerpos anti-tnf, composiciones y métodos para el tratamiento de la espondilitis anquilosante activa.
AU2020311897A1 (en) 2019-07-08 2022-02-03 Research Institute At Nationwide Children's Hospital Antibody compositions for disrupting biofilms
WO2021028752A1 (en) 2019-08-15 2021-02-18 Janssen Biotech, Inc. Anti-tfn antibodies for treating type i diabetes
AU2020408213A1 (en) 2019-12-19 2022-06-23 Quidel Corporation Monoclonal antibody fusions
US20230041211A1 (en) 2019-12-20 2023-02-09 Basf Se Decreasing toxicity of terpenes and increasing the production potential in micro-organisms
US20230061973A1 (en) 2020-02-05 2023-03-02 Larimar Therapeutics, Inc. Tat peptide binding proteins and uses thereof
EP4132971A1 (de) 2020-04-09 2023-02-15 Merck Sharp & Dohme LLC Affinitätsgereifte anti-lap-antikörper und verwendungen davon
CA3175523A1 (en) 2020-04-13 2021-10-21 Antti Virtanen Methods, complexes and kits for detecting or determining an amount of a .beta.-coronavirus antibody in a sample
US20210340524A1 (en) 2020-05-01 2021-11-04 Massachusetts Institute Of Technology Methods for identifying chimeric antigen receptor-targeting ligands and uses thereof
WO2021221782A1 (en) 2020-05-01 2021-11-04 Massachusetts Institute Of Technology Chimeric antigen receptor-targeting ligands and uses thereof
US20230235310A1 (en) 2020-06-04 2023-07-27 Isobionics B.V. Synthetic santalene synthases
CN115867564A (zh) 2020-07-14 2023-03-28 先锋国际良种公司 杀昆虫蛋白及其使用方法
WO2022029494A1 (en) 2020-08-04 2022-02-10 Abbott Rapid Diagnostics International Unlimited Company Assays for detecting sars-cov-2
US20220043000A1 (en) 2020-08-04 2022-02-10 Abbott Laboratories Methods and kits for detecting sars-cov-2 protein in a sample
US11795225B2 (en) 2020-09-11 2023-10-24 Medimmune Limited Therapeutic binding molecules
KR20230066095A (ko) 2020-09-12 2023-05-12 메디뮨 리미티드 항-b7h4 항체-약물 접합체 요법에 대한 점수산정 방법
WO2023102384A1 (en) 2021-11-30 2023-06-08 Abbott Laboratories Use of one or more biomarkers to determine traumatic brain injury (tbi) in a subject having received a head computerized tomography scan that is negative for a tbi
CA3198161A1 (en) 2020-12-01 2022-06-09 Beth MCQUISTON Use of one or more biomarkers to determine traumatic brain injury (tbi) in a subject having received a head computerized tomography scan that is negative for a tbi
EP4015626A1 (de) 2020-12-18 2022-06-22 Isobionics B.V. Enzyme und verfahren zur fermentativen herstellung von monoterpenestern
EP4271998A1 (de) 2020-12-30 2023-11-08 Abbott Laboratories Verfahren zur bestimmung des sars-cov-2-antigens und anti-sars-cov-2-antikörpers in einer probe
MX2023008285A (es) 2021-01-13 2023-09-12 Memorial Sloan Kettering Cancer Center Conjugado de anticuerpo anti-dll3-farmaco.
US20240115720A1 (en) 2021-01-13 2024-04-11 Memorial Sloan Kettering Cancer Center Antibody-pyrrolobenzodiazepine derivative conjugate
UY39610A (es) 2021-01-20 2022-08-31 Abbvie Inc Conjugados anticuerpo-fármaco anti-egfr
BR112023018353A2 (pt) 2021-03-12 2024-02-06 Janssen Biotech Inc Método seguro e eficaz para tratamento da artrite psoriática com anticorpo específico anti-il23
IL305836A (en) 2021-03-12 2023-11-01 Janssen Biotech Inc A method for treating psoriatic arthritis patients with insufficient response to TNF therapy with a specific anti-IL23 antibody
BR112023017490A2 (pt) 2021-03-17 2023-11-07 Receptos Llc Métodos de tratamento de dermatite atópica com anticorpos anti il-13
KR20230158526A (ko) 2021-03-18 2023-11-20 메디뮨 리미티드 Ccr9에 결합하는 치료용 결합 분자
EP4337689A1 (de) 2021-05-12 2024-03-20 Applied Biomedical Science Institute Bindungspolypeptide gegen sars cov-2 und verwendungen davon
WO2022245920A1 (en) 2021-05-18 2022-11-24 Abbott Laboratories Methods of evaluating brain injury in a pediatric subject
IL308607A (en) 2021-05-20 2024-01-01 Janssen Biotech Inc A method for treating inflammatory bowel disease with combined treatment of antibodies to IL-23 and TNF alpha
JP2024521476A (ja) 2021-06-14 2024-05-31 アボット・ラボラトリーズ 音響エネルギー、電磁エネルギー、過圧波及び／又は爆風により引き起こされる脳損傷の診断法又は診断の一助となる方法
EP4367136A1 (de) 2021-07-09 2024-05-15 Janssen Biotech, Inc. Herstellungsverfahren zur herstellung von anti-tnf-antikörperzusammensetzungen
IL309987A (en) 2021-07-09 2024-03-01 Janssen Biotech Inc Production methods for the production of anti-IL12/IL23 antibody compositions
KR20240032991A (ko) 2021-07-09 2024-03-12 얀센 바이오테크 인코포레이티드 항-tnf 항체 조성물의 생성을 위한 제조 방법
WO2023012111A2 (en) 2021-08-02 2023-02-09 Basf Se Novel production of aroma compounds with ionylideneethane synthases
US11807685B2 (en) 2021-08-05 2023-11-07 The Uab Research Foundation Anti-CD47 antibody and uses thereof
WO2023028186A1 (en) 2021-08-27 2023-03-02 Abbott Laboratories Methods for detecting immunoglobulin g, subclass 4 (igg4) in a biological sample
EP4396587A1 (de) 2021-08-31 2024-07-10 Abbott Laboratories Verfahren und systeme zur diagnose von hirnverletzungen
WO2023056268A1 (en) 2021-09-30 2023-04-06 Abbott Laboratories Methods and systems of diagnosing brain injury
CA3236779A1 (en) 2021-10-29 2023-05-04 Janssen Biotech, Inc. Methods of treating crohn's disease with anti-il23 specific antibody
IL312778A (en) 2021-11-15 2024-07-01 Janssen Biotech Inc Methods for treating Crohn's disease with a specific anti-IL23 antibody
IL313021A (en) 2021-11-23 2024-07-01 Janssen Biotech Inc A method for treating ulcerative colitis with a specific anti-IL23 antibody
AU2022413677A1 (en) 2021-12-17 2024-06-27 Abbott Laboratories Systems and methods for determining uch-l1, gfap, and other biomarkers in blood samples
WO2023129942A1 (en) 2021-12-28 2023-07-06 Abbott Laboratories Use of biomarkers to determine sub-acute traumatic brain injury (tbi) in a subject having received a head computerized tomography (ct) scan that is negative for a tbi or no head ct scan
AU2023216317A1 (en) 2022-02-04 2024-09-05 Abbott Laboratories Lateral flow methods, assays, and devices for detecting the presence or measuring the amount of ubiquitin carboxy-terminal hydrolase l1 and/or glial fibrillary acidic protein in a sample
TW202348252A (zh) 2022-02-16 2023-12-16 英商梅迪繆思有限公司 用治療性結合分子治療癌症的組合療法
US20230312703A1 (en) 2022-03-30 2023-10-05 Janssen Biotech, Inc. Method of Treating Psoriasis with IL-23 Specific Antibody
WO2023223265A1 (en) 2022-05-18 2023-11-23 Janssen Biotech, Inc. Method for evaluating and treating psoriatic arthritis with il23 antibody
WO2024006876A1 (en) 2022-06-29 2024-01-04 Abbott Laboratories Magnetic point-of-care systems and assays for determining gfap in biological samples
WO2024059708A1 (en) 2022-09-15 2024-03-21 Abbott Laboratories Biomarkers and methods for differentiating between mild and supermild traumatic brain injury
WO2024059692A1 (en) 2022-09-15 2024-03-21 Abbott Laboratories Hbv diagnostic, prognostic, and therapeutic methods and products
US20240199734A1 (en) 2022-11-22 2024-06-20 Janssen Biotech, Inc. Method of Treating Ulcerative Colitis with Anti-IL23 Specific Antibody

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4237224A (en) * 1974-11-04 1980-12-02 Board Of Trustees Of The Leland Stanford Jr. University Process for producing biologically functional molecular chimeras
US4321365A (en) * 1977-10-19 1982-03-23 Research Corporation Oligonucleotides useful as adaptors in DNA cloning, adapted DNA molecules, and methods of preparing adaptors and adapted molecules
US4366246A (en) * 1977-11-08 1982-12-28 Genentech, Inc. Method for microbial polypeptide expression
US4293652A (en) * 1979-05-25 1981-10-06 Cetus Corporation Method for synthesizing DNA sequentially
US4271145A (en) * 1979-10-22 1981-06-02 The Massachusetts General Hospital Process for producing antibodies to hepatitis virus and cell lines therefor
US4338397A (en) * 1980-04-11 1982-07-06 President And Fellows Of Harvard College Mature protein synthesis
US4879219A (en) * 1980-09-19 1989-11-07 General Hospital Corporation Immunoassay utilizing monoclonal high affinity IgM antibodies
US4362867A (en) * 1980-12-10 1982-12-07 Research Corporation Recombinant cDNA construction method and hybrid nucleotides useful in cloning
US4394443A (en) * 1980-12-18 1983-07-19 Yale University Method for cloning genes
US4490358A (en) * 1982-03-01 1984-12-25 President And Fellows Of Harvard College Screening vaccines and immunization process
USRE32833E (en) * 1982-03-01 1989-01-17 President And Fellows Of Harvard College Screening vaccines and immunization process
US4366264A (en) 1982-04-16 1982-12-28 Stanley Wawzonek Use of calcium metasilicate (wollastonite) as a formaldehyde suppressant for urea formaldehyde resins
DE3300632A1 (de) * 1982-12-13 1984-07-12 Christian Dipl.-Ing. 8900 Augsburg Strobel Verfahren genetischer analyse und synthese
DE3246071A1 (de) * 1982-12-13 1984-06-14 Christian Dipl.-Ing. 8900 Augsburg Strobel Verfahren genetischer analyse und synthese
US4634678A (en) * 1982-12-13 1987-01-06 Molecular Genetics Research And Development Limited Partnership Plasmid cloning and expression vectors for use in microorganisms
DE3303173A1 (de) * 1982-12-13 1984-08-02 Christian Dipl.-Ing. 8900 Augsburg Strobel Verfahren genetischer analyse und synthese
US4719179A (en) * 1984-11-30 1988-01-12 Pharmacia P-L Biochemicals, Inc. Six base oligonucleotide linkers and methods for their use
US4959312A (en) * 1985-05-31 1990-09-25 The University Of Tennessee Research Corporation Full spectrum mutagenesis
US5723286A (en) * 1990-06-20 1998-03-03 Affymax Technologies N.V. Peptide library and screening systems

Also Published As

Publication number Publication date
EP0590689A2 (de) 1994-04-06
IN169027B (de) 1991-08-17
US5723323A (en) 1998-03-03
DE3588239T3 (de) 2007-03-08
AU4434585A (en) 1986-10-23
EP0590689B2 (de) 2006-08-16
WO1986005803A1 (fr) 1986-10-09
DE3587814T2 (de) 1994-11-10
FR2579618B1 (fr) 1987-12-24
SG7992G (en) 1992-03-20
DE3587814D1 (de) 1994-06-09
US20040161816A1 (en) 2004-08-19
DE3590766C2 (de) 1991-01-10
US5976862A (en) 1999-11-02
FR2579618A1 (fr) 1986-10-03
JPS62502235A (ja) 1987-09-03
DE3590766T (de) 1987-04-23
JPH0856667A (ja) 1996-03-05
US5824514A (en) 1998-10-20
CN86102090A (zh) 1986-11-05
HK20292A (en) 1992-03-27
EP0229046B1 (de) 1994-05-04
DE3588239D1 (de) 2002-06-27
EP0590689B1 (de) 2002-05-22
DE3546807C2 (de) 1991-03-28
US5817483A (en) 1998-10-06
EP0229046A1 (de) 1987-07-22
JP2584613B2 (ja) 1997-02-26
DE3588239T2 (de) 2003-01-02
GB2183661B (en) 1989-06-28
EP1186660A2 (de) 2002-03-13
DE229046T1 (de) 1987-12-17
GB2183661A (en) 1987-06-10
DE3546806C2 (de) 1991-03-28
JP2004089197A (ja) 2004-03-25
EP0590689A3 (de) 1994-04-20
US5814476A (en) 1998-09-29
CA1341595C (en) 2009-04-28
GB8628313D0 (en) 1986-12-31
EP1186660A3 (de) 2002-03-20
US6569641B1 (en) 2003-05-27
JP2002325594A (ja) 2002-11-12
CA1339937C (en) 1998-06-30
CH0229046H1 (de) 1998-07-15

Similar Documents

Publication Publication Date Title
IN165561B (de)
DE3690606T (de)
FR2587830B1 (de)
FR2580039B1 (de)
DE3590762T1 (de)
IN164472B (de)
GR852046B (de)
BA96126A (de)
GR852862B (de)
AU3954685A (de)
GR850047B (de)
GR851870B (de)
GR850655B (de)
AU4121285A (de)
GR852885B (de)
IN160614B (de)
BG45210A1 (de)
BG45483A1 (de)
BG45195A1 (de)
BG45438A1 (de)
AU8658089A (de)
BG45466A1 (de)
BG44910A1 (de)
BG45495A1 (de)
BG45480A1 (de)